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Chemotherapy being one of the principle techniques used in cancer treatment, has been applied in 
the treatment of a wide spectrum of cancers. However, this mode of treatment is fraught with a 
myriad of challenges, reducing its effectivity and inducing the need for repeated treatments. Poor 
drug delivery systems or lack thereof, have led to patients suffering unpleasant side effects that 
not only cause collateral damage to their bodies but also reduces the quality of their lives. The 
current array of chemotherapeutic drugs available may be effective in certain cancers, nevertheless 
the need for their optimization is still necessary for better safety, stability and efficiency of 
treatment. Thus the current study was designed to investigate the potential of layered double 
hydroxide (LDH) nanoparticles in the delivery of the broad spectrum anticancer drug, 5-
Fluorouracil (5-Fu). Four LDH nanoparticles, MgAl 2:1, MgAl 3:1, ZnAl 2:1and ZnAl 3:1 were 
successfully synthesized and intercalated with 5-Fu using the calcination reconstruction process to 
form nanohybrids. The LDHs and their nanohybrids, MgAl 2:1-5-Fu, MgAl 3:1-5-Fu, ZnAl 2:1-
5-Fu and ZnAl 3:1-5-Fu were structurally confirmed using XRD, FTIR, UV-Vis, ICP-OES; with 
size, zeta potential and ultrastructural morphology investigated using nanoparticle tracking 
analysis (NTA) and electron microscopy (TEM and SEM). LDHs were characteristically 
hexagonal in shape with sizes ranging from 100 -150 nm, and high zeta potentials enforcing their 
colloidal stability. The successful intercalation of 5-Fu was confirmed from drug encapsulation 
efficiency studies to be between 40-60% in the respective LDHs. Furthermore, drug release studies 
revealed a steady controlled release of the drug over a 7-hour period at pH 4-7, with more than 
60% of the drug being released by the end of this period. In vitro MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide] and SRB (Sulphorhodamine B) cytotoxicity studies on free 
5-Fu and LDH bound 5-Fu in human cell lines, breast adenocarcinoma cell line (MCF-7), 
hepatocellular carcinoma (HepG2), colorectal adenocarcinoma (CaCo-2) and embryonic kidney 
(HEK293), showed a dose dependent cytotoxicity profile with the free 5-Fu being more toxic to 
the cells than the bound drug. This was further confirmed in fluorescent apoptotic studies (dual 
acridine orange and ethidium bromide staining method), where free 5-Fu had a higher apoptotic 
index than the LDH bound 5-Fu 
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The background of the study provides a brief introduction to the study. It further describes the 
challenges faced in anticancer drug delivery systems and how this study will serve to try to 
overcome some of these hurdles. The significance and novelty, including the aims, objectives and 




1.2 Background of Study 
 
The battle against cancer in recent years has presented the scientific world with the challenge of 
finding a safe and effective drug delivery system to deliver anticancer drugs effectively to the 
appropriate affected sites (Tiwari et al., 2012). Although, many drug systems have been developed 
and utilized, there still exists the need for safer and target specific delivery systems for anticancer 
drugs. Administration of anticancer drugs such as 5-Fluorouracil (5-Fu), although effective, does 
present with the problem of collateral damage to unaffected areas in the body, leading to unpleasant 
side effects (Holohan et al., 2013, Tiwari et al., 2012). Nanoparticles in recent years have shown 
potential as drug delivery carriers, due to their nanoscale and chemical properties which enables 
effective encapsulation of drugs.  Amongst the various inorganic nanoparticles being used, the 
layered double hydroxide nanoparticles have also shown some potential in drug delivery (Aguzzi 
et al., 2007, Haley and Frenkel, 2008). Hence, LDHs have been researched as both gene and drug 
delivery vehicles, successfully showing the nanoparticle’s ability to protect, sustain and improve 
on the limitations of many previously studied nanoparticles (Choi and Choy, 2011). The ability of 
LDHs to deliver the hydrophobic drug raloxifene hydrochloride (RH), using the co-precipitation 
method to intercalate the drug, showed the controlled release of RH from the LDH revealing a 
sustained system of drug delivery (Senapati et al., 2016). From the myriad of drug delivery 
vehicles that have been synthesized to date for the purposes of drug delivery, many fail to 
completely eliminate nanoparticle carrier from the body and leading to accumulation of the carrier, 




1.3 Significance and Novelty of Study 
  
Most nanoparticle drug delivery systems do not provide adequate protection or cellular uptake of 
certain drugs. Hence, LDHs are being investigated as a possible alternative option. This study 
examines the potential of two layered double hydroxide nanoparticles (or LDHs) viz. magnesium 
aluminium (MgAl 2:1-LDH and MgAl 3:1-LDH and) as well as zinc aluminium (ZnAl 2:1-LDH 
and ZnAl 3:1-LDH), to deliver the anticancer drug, 5-Fluorouracil, a primary drug for targeting 
colorectal cancer, to mammalian cancer cells in vitro. This study further seeks to understand the 
chemistry of these nanostructures, and how their morphology favours protection and controlled 
release of the drug in the desired cells or tissue. These two LDHs are further compared with 
regards to their limitations and advantages. Thus the roadmap of this thesis is such that past 
literature and research findings are critically evaluated to help improve on the knowledge of the 
LDHs’ applicability as drug delivery systems. Comparative studies look at how the two 
synthesized LDHs, namely, MgAl-LDH and ZnAl-LDHs differ in their respective characteristics 







The principle aim of our study is to first synthesise and subsequently evaluate the ability of two 
distinctly different layered double hydroxides (MgAl 2:1-LDH, MgAl 3:1-LDH, ZnAl 2:1-LDH 
and ZnAl 3:1-LDH) to encapsulate a very hydrophilic drug, 5-Fluorouracil (5-Fu), and deliver it 
efficiently to mammalian cancer cells. We also examine their drug binding and release properties 
to ascertain their suitability as drug carriers. 
 
 
1.5 Objectives  
 
 To synthesize and fully characterize the MgAl-LDH and ZnAl-LDHs using ICP-
OES, FTIR, UV-spectroscopy, TEM, SEM, and Nanoparticle Tracking Analysis 
(NTA) 
 To intercalate the drug, 5-Fu, into the LDHs and fully characterize the binding. 





 To determine the advantages, if any, of LDH bound 5-Fu versus the freely 




1.6 Outline of the Dissertation. 
 





1.6.1 Chapter 1 
 
This chapter provides a brief background to the study, rationale and significance for the study of 
LDHs as potential drug delivery vehicles, as well the outline of the whole thesis. A note is made 
as to the novelty of the research. Within this chapter the primary aims and objectives are stated 




1.6.2 Chapter 2 
 
The detailed literature survey forms the basis of this chapter. Subtopics leading to a better 
understanding of the past to present research on layered double hydroxides (LDHs) are discussed. 
This is to introduce the nanoparticle and its role over the past years in medicine and in general. 
Limitations encountered by researchers are outlined, including possible methods for improving 
this drug delivery system. Background to the analytical techniques used in this project are detailed 








1.6.3 Chapter 3 
 
This chapter, is written in paper format. The title of the article is “The Application of MgAl 
Layered Double Hydroxides as Potential Anticancer Drug Delivery Vehicles”. This article 
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examines the two synthesised magnesium aluminium layered double hydroxides (namely, MgAl 
2:1-LDH and MgAl 3:1-LDH) and their application in the effective delivery of 5-Fu. Conclusions 





1.6.4 Chapter 4 
 
This chapter is written in paper format similar to chapter 3, but looks at the zinc and aluminium 
LDHs. The title of the article is “The Application of ZnAl Layered Double Hydroxides as 
Potential Anticancer Drug Delivery Vehicles”. This article looks at ZnAl 2:1-LDH and ZnAl 
3:1-LDH, and their application in the effective delivery of 5-Fu. Conclusions and future 




1.6.5 Chapter 5 
 
This chapter provide the conclusions deduced from the study, and highlights further 
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Cancer is a disease characterized by uncontrollable cell growth resulting in the formation of 
cancerous cellular clusters referred to as tumours. Tumours grow and inhibit the normal 
functioning, among many other factors, of various organs in the body through the release of 
hormones that significantly alter organ function (Cole, 1973, Kamb et al., 2007, Karpanen et al., 
2001). Through a process of metastasis, the cancerous cells spread throughout the body via the 
blood or lymphatic systems (Kucia et al., 2005). Various factors, many of which are known, 
contribute to the development and subsequent spread of cancer. Mutational errors during cell 
division, aging, tobacco intake, sun exposure, radiation exposure, potential carcinogenic 
chemicals, viruses and bacteria, certain hormones, alcohol, poor diet, and lack of physical activity 
are just some of the known causes of cancer (Cancer.Net, 2015, MedicineNet.com, 2016). The 
genes commonly implicated in cancer initiation and development, are the oncogenes that are 
activated and tumour suppressor genes that become inactivated, resulting in these genes not 
performing their normal functions in the body. Figure 2.1 provides a projection for the increase in 























Figure 2.1 Data from the United States Centre for Disease Control illustrating the expected increase 









From the data compiled by the Centre for Diseases Control and Prevention (CDC) on the 
prevalence of cancer worldwide, approximately 14.1 million cases of cancer are diagnosed each 
year and a staggering 8.2 million people die from cancer annually. In 2015 the number of reported 
cancer cases rose to 19.3 million. Of the various types of cancers diagnosed worldwide, (Figure 
2.2), the most prominent of these were lung cancer (13%), breast cancer (12%), colorectal cancer 
and other stomach cancers (17% combined), prostate cancer (8%), liver cancer (6%) and cervical 
cancer (4%) (CDC, 2016). A challenge facing researchers is in finding an appropriate drug delivery 
system to allow for the safe delivery of the existing drugs, while minimizing the cost and time 





























2.2 Anticancer Drugs 
 
Chemotherapy is one of the common modes of cancer treatment involving the use of one or more 
anticancer drugs or chemicals for the purposes of destroying cancer cells. Research has shown that 
cancerous cells present a satisfactory apoptotic response after exposure to various 
chemotherapeutic drugs (Liu, 2009). The term “anticancer drugs” or “antineoplastic drugs” refers 
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to a number of drugs developed for the effective treatment of cancer. The application of these 
anticancer drugs or chemicals in treatment against cancers is therefore termed chemotherapy (Rang 
et al., 2016). It is worth noting that chemotherapy is a very aggressive and systemic form of 
chemical drug therapy which has various implications for the patient (Chen, 2016). The main 
reason this form of therapy is applied is primarily because it lowers the total number of cancer 
cells significantly, in addition to reducing the spread of the cancer and reduction of tumour sizes. 
This method of treatment is also advantageous in a sense that it is non-invasive and limits the risk 
of infection. However, patients do have to consider a number of implications accompanying the 
use of chemotherapy, such as the high cost of the treatment, time spent on sessions, unpleasant 
side effects, and as well as the need to use other drugs to suppress some of these side effects (Chen, 
2016). 
 
Anticancer or chemotherapeutic drugs can be categorized into several major classes: alkylating 
agents, antimetabolites, natural products, and hormones (Rang et al., 2016). However, some drugs 
developed with the purpose of combating cancers may not fall under the above mentioned classes 
of drugs although they are applied in chemotherapy. Figure 2.3 outlines the various drugs currently 




























































Figure 2.3 Chemotherapeutic drugs and their mechanisms of action (Pharmafactz, 2016) 
 
 
2.2.1 Alkylating Agents 
 
 
Alkylating agents are the one of the oldest group of drugs used in chemotherapy. They are 
genotoxic drugs (i.e. toxic to nucleic acids). These agents bind to the DNA and interrupt its 
replication and transcription. The purpose of these drugs is to induce DNA damage in cancerous 
cells leading to their apoptosis. Alkylating agents act by replacing a hydrogen atom by an alkyl 
radical through an electrolytic attack. However, this compound can then also react with molecules 
containing an atom in a lower valence state that will can also undergo an electrolytic attack (dos 
Santos Guimarães et al., 2013). Alkylating agents can work at any point during the cell cycle and 
are thus known as cell cycle-independent drugs (dos Santos Guimarães et al., 2013, Lind, 2008). 
Some examples of alkylating agent are mustard gas, nitrosoureas and alkyl sulfonates (dos Santos 
Guimarães et al., 2013). However, a study conducted by (Hawkins et al., 1992) showed an 
association of secondary leukaemias with patients that had been treated for cancer previously. In 
this study, of a cohort of 16 422 one year survivors of childhood cancer diagnosed in Britain 
between the years 1962 and 1983, 22 patients showed the development of secondary leukaemia. 
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Hence, it was concluded that the accumulation of the alkylating agents as well as other drugs led 







Antimetabolites are cell cycle dependent cytotoxic agents, which were developed more than 65 
years ago, and are hence among the initially used chemotherapy agents. They can be divided 
according to their structure and function, as folic acid analogs, purine analogs, pyrimidine analogs 
and cytidine analogs (Abraham et al., 2007, Lind, 2008). These antimetabolites work by halting 
DNA or RNA synthesis and replication, and by inhibiting essential enzymes needed to carry out 
these processes. Through disincorporation, apoptosis is induced as the damage to DNA leads to 
programmed cell death. Unlike their cell cycle independent counterparts (alkylating agents), 
antimetabolites work only during the DNA synthesis phase or the S-Phase. Prominent examples 
of antimetabolite chemotherapeutic agents include 5-Fluorouracil which is a pyrimidine analog 
(Abraham et al., 2007), and methotrexate (Praetorius and Mandal, 2007) 
 
 
2.2.3 Hormones and Antibiotics 
  
 
Hormones such as glucocorticoids, progestins, antioestrogens, antiandrogens, and Selective 
Estrogen Receptor Modulators (SERMs), are just a few of the variety of hormones used in the fight 
against cancer, through systematic and dose dependent delivery to patients (Brunton et al., 2011). 
Antibiotics such as anthracyclines, bleomycin, antracenediones and doxorubicin have also been 




2.2.4 Nucleic acids 
 
Gene therapy is a term used to describe the application of nucleic acids for therapeutic purposes 
(Flotte and Carter, 1995, Niidome and Huang, 2002). Various genetic diseases that have been 
addressed using this form of therapy, especially, cystic fibrosis (Colledge and Evans, 1995, 
Griesenbach and Alton, 2013), Parkinson's disease (Mittermeyer et al., 2012, Palfi et al., 2014), 
as well as other forms of inherited or acquired genetic diseases such as cancer. Nucleic acids have 
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been applied in monotherapy or in combination with other regimens such as radiation and 
chemotherapy (Balasubramanian and Neidle, 2009, Schwarzenbach et al., 2011). 
 
Nucleic acids that have been applied in cancer therapy specifically include plasmid DNA (pDNA), 
synthetic nucleic acids such as antisense oligonucleotides, small interfering RNAs (siRNA), micro 
RNA (miRNA), messenger RNA (mRNA), and other double stranded RNAs such as polyinosine-
cytosine (pIC) (Sajeesh et al., 2014). Nucleic acids work in various ways intracellularly; some may 
render gene knockdown or silencing (siRNAs), while others deal with the replacement or 
substitution of the defective genes (pDNA) with a normal one. Therefore, pDNA vectors are 
utilized for intra-nuclear delivery to replace or to substitute specific genetic functions in the 
targeted cell resulting in an addition of a gene function. On the other hand, loss of gene function 
is often achieved through intra-cytoplasmatic delivery of synthetic antisense oligonucleotides, or 
siRNA reducing the expression of endogenous genes in a sequence-specific manner (Kim et al., 
2006). Thus, the mechanisms of the therapeutic effects of nucleic acids are diverse and include 
(among many actions) the inhibition of neoangiogenesis, activation of cytokines or 
immunostimulatory responses (Wagner et al., 2004), induction of apoptosis.
Reduction of tumor cell proliferation or strategies to replace deleted genes or to over-express 




2.2.5 Side Effects of Chemotherapeutic agents 
 
 
Chemotherapy drugs on their own, although effective in many cases, present adverse side effects 
due to various factors that affect their efficiency (de Mol et al., 2016, Monje and Dietrich, 2012). 
Lack of cell / tumour specific targeting (Pabla and Dong, 2012), unknown doses or concentrations 
of the drug once inside the body, and over expression of the functions of the specific 
chemotherapeutic agents, (Song et al., 2014), can all produce unwelcome side effects. 
 
Side effects commonly experienced by patients include (but are not limited to), hair loss, decreased 
blood cell count, cardiac dysfunction, diarrhoea, hyperglycaemia, vomiting, skin irritation, 
decrease in fertility and libido, immunosuppression and myelosuppression (in the case of bone 
marrow paralysis leading to a decrease in white blood cell count or a total destruction of the bone 
marrow), typhlitis (an intestinal infection), anaemia which can ultimately lead to fatigue, and the 







2.3 Anticancer Drug: 5-Fluorouracil (5-Fu)  
 
 
This research project examines the delivery of 5-Fluorouracil (5-Fu) (trade name Adrucil) using 
layered double hydroxides (LDHs) as the drug carriers. 5-Fluorouracil (5-Fu) is a widely used 
anticancer drug. It has been used in cancer treatment since 1959, when it was officially 
recommended as an anticancer drug (van Kuilenburg and Maring, 2013). However, its discovery 
goes back to the year, 1954, when Abraham Cantarow and Karl Paschkis discovered that liver 
tumours absorbed radioactive uracil more easily than normal liver cells. Earlier discoveries showed 
that fluorine in fluoroacetic acid inhibited a vital enzyme, leading to the synthesis of fluorouracil, 
and the discovery of the drug, 5-Fluorouracil. Since then 5-Fu has been utilized for the treatment 
of colorectal, breast, head and neck, thymus, bladder, and gastrointestinal cancers, in addition to 
neuroendocrine tumors among others (Folprecht et al., 2004, Prado et al., 2007, van Kuilenburg 
and Maring, 2013). 
  
With respect to its chemistry, 5-Fu is a heterocyclic aromatic organic compound. Its structure is 
similar to that of the pyrimidine bases of deoxyribonucleic acid (DNA) and ribonucleic acid 
(RNA). 5-Fluorouracil is an analogue of uracil with a fluorine atom at carbon-5, replacing 
hydrogen. It is highly hydrophilic and has a high solubility in basic water (Li et al., 2008). Figure 


















    
   
 
 









2.3.1 Mechanism of Action of 5-Flurorouracil 
 
 
The mechanism of action of 5-Fu has been proposed by several researchers. It has been found that 
5-Fu rapidly enters the cancerous cell using the same facilitated transport mechanism as uracil, 
where it is converted intracellularly into the following metabolites: fluorodeoxyuridine 
monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP), and fluorouridine 
triphosphate (FUTP) (Maxwell et al., 2003). These active metabolites then disrupt ribonucleic acid 
synthesis and the action of thymine synthase (TS), an essential enzyme involved in the catalysis 
and biosynthesis of thymidylate. This enzyme also plays a role in the regulation of protein 
synthesis and other apoptotic processes that occur within the cell (Li et al., 2013, Longley et al., 
2003) 
 
It has been observed that the rate-limiting enzyme in 5-Fu catabolism, dihydropyrimidine 
dehydrogenase (DPD), converts 5-Fluorouracil to dihydrofluorouracil (DHFU). More than 80% of 
the administered 5-Fu is catabolized primarily in the liver, where DPD is abundantly expressed 





































2.3.2 Side Effects of 5-Fluorouracil 
 
 
Some of the noted general side effects of administered 5-Fu, include diarrhoea, nausea and possible 
occasional vomiting, mouth sores, poor appetite, watery eyes, sensitivity to light (photophobia), 
taste changes, metallic taste in mouth during infusion, discoloration along the vein through which 
the medication is given, and low blood cell counts (Navigating Cancer, 2016). The 5-Fu which is 
available commercially usually as Efudex solution (2-5%) and a topical cream (2-5%), also comes 
with various side effects when used by the patient (Weinreb, 1987). These include burning, 
crusting of skin, allergic contact dermatitis, erosions, erythema, hyperpigmentation, irritation, 
pain, photosensitivity, pruritus, scarring, rash, soreness and ulcerations (Weinreb, 1987). Cases of 
miscarriage and birth defects such as ventricular septal defects have also been reported when 
Efudex was applied to areas of the mucous membrane (Cardonick and Iacobucci, 2004). 
Leucocytosis is another haematological side effect commonly observed (Cardonick and Iacobucci, 
2004, Navigating Cancer, 2016). 
2.3.3 Delivery of 5-Fluorouracil 
 
 
Studies conducted both in vitro and in vivo in the delivery of deliver 5-Fu using poly (lactide-co-
glycolide) (PLGA) nanoparticles, have shown that PGLA helps to improve 5-Fu’s oral 
bioavailability. Kumari et al., 2016). Furthermore, chitosan nanospheres have also been 
successfully used in the delivery of 5-Fu (Cavalli et al., 2014). These drug loaded nanospheres 
were prepared using a technique derived from a combination of the coacervation and the emulsion 
droplet coalescence methods. The encapsulation efficiency achieved was approximately 70% 
(Cavalli et al., 2014). Cytotoxicity profiles in the cancer cell lines HT-29 and PC-3, revealed that 
in comparison to freely delivered 5-Fu, the chitosan encapsulated 5-Fu produced lowered 
cytotoxicity (Cavalli et al., 2014). 5-Fu was also successfully delivered using non-ionic surfactant 
vesicles (niosomes), prepared by the hand shaking method (HSM) (Marwa et al., 2013), as an 
alternative to delivery using liposomes (Ahmad et al., 2014). Antibodies have also been used to 
deliver 5-Fu. Antibody systems such as the Monoclonal Antibody Modified Bovine Serum 
Albumin Nanoparticles (MAMBSA), were used in the delivery of 5-Fu (Fadaeian et al., 2015), 
which showed a more targeted mode of delivery of the drug, thereby lowering the risk of collateral 
cell death. Other nanoparticles such as gold nanoparticles (GNPs) have also been used in the 
delivery of 5-Fu (Dianzani et al., 2014). Current research looking into the delivery of 5-Fu using 
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Layered Double Hydroxides has also emerged, and presents with higher possibilities a simplistic 
yet effective method of 5-Fu delivery (Kim et al., 2014). 
 
 
Combination therapy with 5-Fluorouracil co-delivered along with methotrexate, another 
anticancer drug has also been accomplished. Nanocomplexes comprising MTX/LDH (ML), 5-
Fu/LDH (FL), and (MTX + 5-Fu)/LDH (MFL) were also successfully synthesised (Kim et al., 
2014). Using the HeLa and HEK293 cell lines, the study indicated that not only was the 
cytotoxicity of 5-Fu significantly reduced due to encapsulation within the LDH, but that its 
combination with methotrexate resulted in higher apoptosis in the cancerous cells (HeLa) whilst 
significantly reducing toxicity to the control cell line (HEK293) (Kim et al., 2014, Li et al., 2004, 
Wang et al., 2005b). 
 
Over the past 50 years, despite its many advantages, clinical applications have been greatly limited 
due to drug resistance to 5-Fu. The overall response rate for advanced colorectal cancer has been 
reported to be only 10–15% for the 5-Fu alone, but the combination of 5-Fu with other anticancer 
drugs improved the response rates to 40–50% which is still needs improvement (Zhang et al., 
2008a). A myriad of pharmaceutical companies has conducted studies examining the possibilities 
of combination therapy of various other anticancer drugs with 5-Fu. One such study, conducted by 
the company Sanofi-Aventis, looked into the effects of the combination therapy of oxaliplatin /5-
Fluorouracil/ leucovorin for the treatment of metastatic colon or rectum carcinomas that had 
progressed for six months, following the first time treatment with a combination drug called 
eloxatin. An injection containing infusional 5-Fu and leucovorin (LV) was then administered 
(Sanofi-Avecntis, 2002). Eloxatin or otherwise known asoxaliplatin, is an organoplatinum 
alkylating agent, which increased the tumour response overall. This drug is FDA (Federal Drug 
Agency) approved, and was first introduced in France in 1996 and in Europe in 1999, and has since 





2.4 Nanotechnology in Medicine 
 
 
Nanotechnology, a multidisciplinary science presents a cutting edge form of technology with 
opportunities for broader and more efficient modes of drug delivery. The application of 
nanotechnology in medicine is referred to as nanomedicine. Nanotechnology is defined as the 
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understanding, control and tolerance of matter (nanomaterials or nanoparticles) generally within 
the 1-100 nm dimension range, and their application in various functions (Sanofi-Avecntis, 2002, 
Zhang et al., 2008a). Nanoparticles have unique physicochemical properties such as ultra-small 
size, large surface area to mass ratio, and high reactivity that allows for more efficient use. These 
properties can be exploited to improve on the limitations found in current and previously existing 
traditional therapeutic and diagnostic agents. Furthermore, many nanoparticles have shown lower 
cytotoxicity, an efficient and non-invasive form of administration, extended half-life of any 
biomaterial they carry, and the potential to reduce the cost of health-care (Zhang et al., 2008b). 
Organic and inorganic nanoparticles have been utilized in a myriad of therapeutic applications, 
viz. fluorescent biological labels, drug and gene delivery vehicles, protein detectors, DNA 
structure probes, in-tissue engineering, tumour destruction via heating (hyperthermia), separation 
and purification of biological molecules and cells, as MRI contrast enhancers and in phagokinetic 
studies (Huang et al., 2007, Lohse and Murphy, 2012, Novio et al., 2013, Salata, 2004). Some of 
the commonly used nanoparticles to date include lipid and polymers nanostructures, such as 
liposomes, dendrimers and chitosan (Fu and Yao, 2001, Novio et al., 2013, Zhang et al., 2014). 
Inorganic nanoparticles that have been used include carbon nanotubes, gold, silver, calcium 
phosphate, silicon oxides, iron oxides, and layered double hydroxides (LDHs) (Bhattacharyya et 





2.5 Drug Delivery Systems (DDS) 
 
 
Chemotherapy requires the delivery of the drug to the site of cancer growth, to reduce and or halt 
the further spread of the cancerous cells. One of the main challenges facing drug delivery is the 
concept of "targeted delivery". Over a century ago researchers had already asked the major 
question: Can a drug be developed such that it can be targeted to the site but not cause collateral 
damage to healthy cells as a "Magic Bullet"? (Petrak, 2005, Tiwari et al., 2012). Hence, this was 
a clear concern from the early years, but with the recent developments in the synthesis of new and 
appropriate targeted drug delivery system (DDS or TDDS), the dream of targeted delivery could 
become a reality (Petrak, 2005). Developing a new drug molecule that is site specific, is not only 
expensive but also time consuming. This has hence driven the need to develop efficient delivery 
systems for the existing therapeutic drugs as well (De Jong and Borm, 2008). A drug delivery 
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system must, along with its other properties, be able to target the drug to the specific site where 
required, reduce the collateral toxicity of the drug being delivered and offer bioavailability of the 
drug. The drug delivery system must also comprise: (i) high drug encapsulation and sustained 
controlled release (ii) appropriate formulation and shelf-life (iii) biocompatibility (iv) 
biodistribution and targeting, and lastly (v) functionality (De Jong and Borm, 2008). Another 
essential factor to consider in a DDS is the rate of the drug elimination from the body (Petrak, 
2005). It is important that the carrier must not release the drug prematurely (Hashida et al., 
 
2002), but on the other hand, it should not bind the drug too tightly that it prevents its easy release. 
If it is eliminated from systemic circulation rapidly and before it can be delivered to the target site, 
the amount of conjugate at the target site might be insufficient to provide the required 
concentration of the free (unbound) drug, and to elicit the desired therapeutic effect. The design 
and the production of the drug carrier system needs to remove all nonspecific interactions 
occurring between the DDS and the environment of the systemic compartment (De Jong and Borm, 
2008, Hashida et al., 2002). One of the advantages of using nano-DDSs for the delivery of drugs 
is that these nanocarriers can become readily attracted to and concentrated at tumour, inflammatory 
and antigen sampling sites, through the enhanced permeability and retention (EPR) effect of the 
vasculature (Prabhakar et al., 2013). Some hydrophobic polymeric nanoparticles can act as drug 
depots, which is largely dependent on the carrier design, and its ability to allow for greater 
bioavailability of the drug. Drug loading and release are of the utmost importance in drug delivery 
(Singh and Lillard, 2009). Loading characteristics of a nanoparticle are usually predetermined 
depending on the methods of formulation. The first method, is the incorporation of the drug at the 
time of nanoparticle formulation or secondly, the encapsulation of the drug after formulation of 
the nanoparticle (Singh and Lillard, 2009). These methods will determine the rate of release of the 
drug, its concentration in the nanoparticle, as well as the degree of protection conferred by the 




2.6 Layered Double Hydroxides (LDHs) 
 
 
Layered double hydroxides (LDHs), better known as hydrotalcite-like compounds (HTCs) were 
first introduced to the scientific world in 1842 in Sweden as hydroxycarbonates of magnesium and 
aluminium that occur naturally from contorted plates and fibrous masses. The first formula 
([Mg6Al2(OH)16CO3.4H20]) for these layered double hydroxides was then presented at the 
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University of Florence, Italy by Professor Mannase (Rahman and Al-Deyab, 2011). Layered 





) x/m·nH2O] (x = 0.2–0.4; n = 0.5–1), where M
II
 represents a divalent 
metal cation such as Mg2+ and Ca2+ , MIII a trivalent metal cation such Al3+, Cr3+ and Fe3+, and 
A
m -
 an anion (Zhang et al., 2014). Each cation in the LDH layers is surrounded by six OH
−
 ions, 
forming an octahedral subunit that share edges which can be expanded forming a two-dimensional 
layer, which in turn can expand infinitely (Rahman and Al-Deyab, 2011, Zhang et al., 2014). 
Figure 2.6 provide an illustration of the LDH structure and its chemical components. The 
magnesium and aluminium composed LDHs have structural similarities to brucite. In brucite, 
magnesium cations are located at the centre of the octahedral, which contain hydroxyl anions on 
their vertices (Rahman and Al-Deyab, 2011). These sections are organised into neutral layers 
forming a honeycomb-like structure that is hydrogen bonded (Arruda et al., 2013). The LDH 
structure is positively charged due to the presence of anions and water molecules between the 
cationic layers, giving the structure an ordered interlayer domain. Electrostatic interaction holds 
the layers of the LDH, unlike the hydrogen bonding seen in the brucite structure (Rahman and Al-
Deyab, 2011). Any anion can be intercalated between the cationic layers of the LDH as long as 
those anions do not disturb the metal ions that form the brucite like structure, and they have 
sufficient charge density. Some examples of anions that have been intercalated include carbonates, 
nitrate chlorides and fluoride anions (Bao et al., 2011). Numerous studies have also reported the 
intercalation of large organic anionic substances such as DNA and RNA, as seen in some recent 
applications of LDHs as gene delivery vehicles (Balcomb et al., 2015, Ladewig et al., 2010); and 
also carboxylates, dicarboxylates, alkylsulfates and alkanesulfonates (Bao et al., 2011). These 
molecules often range in size from 20 nm to 150 nm depending on the mode of synthesis. This 
varied range allows for the versatility of the type of applications for the LDH (Bao et al., 2011, 



































Figure 2.6: Schematic illustration of the hierarchical organisation of the layered double hydroxide structure 





2.6.1 Applications of Layered Double Hydroxides 
 
 
For many centuries LDHs have been used as ceramic precursors and often used to make clay pots, 
etc. Their recent introduction in the world of nanotechnology came when at the time when they 
were first being utilized as catalysts for hydrogenation, polymerization and steam reforming, and 
further as ion exchangers, molecular sieves, absorbance molecules, halogen scavengers, PVC 
stabilizers, and in waste water treatment applications among others (Ladewig et al., 2010). Figure 
2.7 highlights some of the commercial applications of LDHs. The environmental applications of 
LDHs can be extended by various modifications. Modification of LDHs with organic anions 
allows adsorption of neutral or even positively charged apolar species in the interlayer (gallery 
space) or on the surface of the solids, while the intercalation of polydentate ligands such as citrate, 
malate and ethylenediaminetraacetate (EDTA) modifies the metal ions uptake capacity of the 
















































2.6.2 Properties of Layered double hydroxides 
 
 
LDHs exhibit properties such as a high specific surface area (300 ± 100 m
2
/g), and a "memory 
effect" which allows for reconstruction under mild conditions. It has been reported that the 
calcination of synthetic hydrocalumite (a calcium aluminium LDH) at temperatures ranging from 
500-900 C, led to the formation of crystal mayenite (Ca12Al14O33) and lime (CaO). However, after 
exposure to deionized water the structure of hydrocalumite was completely recovered at room 
temperature (Del Hoyo, 2007, Mascolo and Mascolo, 2015). Layered double hydroxides also have 
a buffering property, as mentioned earlier, which is due to the anion exchange property that they 
have. Hence, the main features of these solids are, a high anion exchange capacity (around 3 
meq/g), the instability of the layers at low pH, and the capacity to reconstruct its lamellar structure 





2.6.3 LDHs for drug delivery 
  
 
There have been recent reports on the pharmaceutical application of LDHs as drug delivery 
vehicles, which have proposed that LDHs are great vehicles in drug delivery, in the sense that they 
can intercalate and deintercalate anionic substances providing a system that allows for controlled 
release of drugs (Del Hoyo, 2007). Some of the drugs that have been intercalated thus far within 
LDHs, include ibuprofen, isofamide, camptothecin, protocatechuic acid, etoposide, ciprofloxacin 
(Gu et al., 2014), α-methyl-4-(2-methylpropyl) benzene acetic acid, diclofenac (Khan et al., 2001) 
and [2-(2, 6-dichloro-phenylamino)-phenyl] acetic acid (Rives et al., 2014). These drugs are often 
used for treatment of acute flares and inflammation, but present limitations in the sense that they 
affect the normal functioning of the central nervous system (CNS) in some patients, as well as a 
host of other detrimental effects, mostly seen in chemotherapy patients (Rives et al., 2014). When 
intercalated into LDHs, these drugs exhibited a controlled system of release, resulting in the 
lowering of some of the side effects of “free” drug delivery (Del Hoyo, 2007). This recent surge 
toward drug intercalation has therefore led to numerous experiments that aim to intercalate 
different types of anticancer drugs into the LDHs e.g. methotrexate (MTX) (Bullo Saifullah, 2015, 
Lindgren et al., 2006). Some of the drugs that have been previously intercalated within LDHs for 
biomedical purposes are listed in Table 2.1. For the purposes of this project we looked at the two 















Table 2:1 Illustration of LDH-drug formulations and their various applications 
 
Type of formulation Name of Formulation Type of Disease 
   
Anticancer formulation Methotrexate LDHs (MgAl) Bone cancer, leukaemia 
   
 Ifosfamide LDHs (MgAl) paediatric, adult tumours and 
  lymphomas 
   
 camptothecin LDHs (MgAl) lung cancer , ovarian cancer , 
  stomach cancer 
   
 Protocatechuic acid cervix, breast ,human leukaemia 
 LDHs( ZnAl)  
   
 Etoposdie Mg/Al small-cell lung carcinoma, gastric 
 LDHs cancers, 
   
  malignancies 
   
 
Ciprofloxacin LDHs (MgAl 
and ZnAl) Adenocarcinomic, Epithelial cancer 
  cell line 
   
   
Antimicrobial Ciprofloxacin LDHs (MgAl) pseudomonas aeruginosa 
   
Formulation hippuric acid ZnAl P. Aeruginosa, staphylococcus 
   
 Benzylpenicillin-MgAl Micrococcus lysodeikticus 
 LDHs  
   
 amino acid -MgAl P. Aeruginosa, staphylococcus 
 LDHs  
   
 AgNpbio-MgAl LDHs Escherichia Coli, S.aureus 
   
 AgNpbio-ZnAl LDHs A. aureus (ACTCC 25923) 
   
 Zn-Ti LDHs Saccharomyces cereviciae 
   
Antituberculosis formulation PAS ZnLH M. tuberculosis 
   
 Cinnamic acid ZnLDH Protection form UV Radiation 
   
 Cinnamic acid Zn/Al Protection form UV Radiation 
   
 Benxophenone-4-ZnAl Protection form UV Radiation 
   
Gene delivery formulation DNA LDHs (MgAl) DNA Protection 
   
Gene delivery formulation 
plasmid DNA LDHs 
(MgAl) enhanced siRNA stability 
   
 siRNA LDHs (ZnAl) cancer treatment 
   






2.6.4 LDH nanoparticle cellular uptake and release mechanisms 
 
 
The cellular uptake of LDHs and LDH nanohybrids have d endocytosis is the main pathway in 
which the LDHs are internalised in mammalian cells (Figbeen the focus of some studies (Choy et 
al., 2000). This has led to the proposal that clathrin-mediateure 2.8). Further research endeavours 
have also demonstrated that in both cell bodies and neurons (PC12 cells), the internalisation of 
siRNA-LDHs is through clathrin mediated endocytosis, with subsequent retrograde transport to 
the cell body followed by efficient release into the cytoplasm (Wong et al., 2010). LDHs exhibit a 
property called the proton sponge effect, due to their high buffering capacity. This plays a crucial 
role in the release of the LDH's contents into the cell, since due to this proton sponge effect, the 
endosomal compartment containing the nanoparticle raptures and exposes the biomolecules within 
the LDH (Figure 2.8). It was also demonstrated that in tumours or other immortalized cell lines, 
internalized LDH nanoparticles move from the early endosomes (pH 6.2) to the late endosomal 
compartment (pH 5–6) throughout various stages in the cell, further confirming the pH dependent 
release of biomolecules (Wong et al., 2010). LDHs are excocytosed from the cell after their 
intended function is completed. (Wong et al., 2010). 
 
Figure 2.8 provides an overview of how the mechanism of both internalization and release of 
encapsulated contents takes place with LDHs. The huge advantage of LDHs is that due to cancer 
cells having anaerobic cellular conditions they easily release their contents when the pH is lowered 
in these cells (Del Hoyo, 2007, Rojas et al., 2015). The lowered pH of cancer cells is due to the 
Warburg effect (Gatenby and Gillies, 2004), which refers to the observation that most cancer cells 
predominantly produce energy by a high rate of glycolysis, followed by lactic acid production in 
the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of pyruvate 
in mitochondria as in most normal cells (Alfarouk et al., 2011, Kim and Dang, 2006, Vander 















































Figure 2.8: Illustration of the cellular uptake of LDH-drug nanocomplexes (1) LDH-drug nanocomplexes 






2.7 Intercalation of Chemotherapeutic drugs in LDHs 
 
 
2.7.1 Alkalisation of 5-Fluorouracil 
 
5-Fu is a neutral weak acid and several studies have reported on the difficulty of intercalating it 
into various host nanoparticles. One study, however, showed that following treatment with alkali, 
interestingly, the resulting conjugate base was anionic and could be intercalated in the MgAl-LDH 
(Wang et al., 2005b). For the purpose of this project the main nanocomplex synthesis route taken 
was the reconstruction route, together with treating the drug with alkali. Many other factors may 





































The co-precipitation technique is perhaps the most commonly used, and the simplest method of 
drug encapsulation within LDHs. In this procedure, the drug solution is added drop-wise to an 
aqueous solution of two different metals that are used as precursors. This is followed by the gradual 
addition of an alkaline solution to the mixture with vigorous stirring under a nitrogen atmosphere, 
until a final pH of 10 is reached (Barahuie et al., 2014). The mixture is then aged at 80 ºC and the 
resultant slurry was filtered, washed with deionized water, and finally dried in an oven at 60 ºC 
(Barahuie et al., 2014). This method produces large quantities of LDH nanoparticles and the 
packing density of the interlayer anion is diverse due to variable M+2/M+3. Although a large 
number of molecules can be incorporated using this method, there is a significantly higher uptake 
of carbon dioxide and incorporation of unwanted hydroxide anions from the reaction mixture 
(Alcantara et al., 2010, Barahuie et al., 2014). 
 
 
2.7.2 Ion-Exchange route 
 
 
For unstable metal cations or intercalated anions, methods such as the co-precipitation method are 
not effective. For these species the ion-exchange method is more effective and is usually favoured. 
A solution containing the anionic species is added to an aqueous solution containing the LDH. The 
reaction mixture is kept at pH 7–10 by simultaneous addition of an alkaline solution, and the 
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suspension formed is vigorously stirred at room temperature. The slurry is then aged at 80 ºC and 
washed as in the co-precipitation method (Barahuie et al., 2014). Factors such as anion affinity, 





2.7.3 Calcination / Reconstruction 
 
 
For our study we used the calcination or reconstruction method to encapsulate 5-Fu within the two 
types of LDH synthesized. For this route, LDHs are synthesized through precipitation without 
adding the alkalized drug. The LDHs are then calcined at 400 C. Thereafter, the drug solution is 
vigorously mixed whilst adding the respective LDH powders, to form the drug containing 




2.7.4. Other methods of encapsulation 
 
 
Hydrothermal and urea hydrolysis methods have also been previously used to incorporate anionic 
species such as drugs into LDHs. The LDH prepared by urea hydrolysis and hydrothermal methods 
have homogeneous sizes, and platelet-like primary particles with well-defined hexagonal shapes 
and good crystal quality (Barahuie et al., 2014) 
  
 
2.8 Experimental Techniques  
 
2.8.1 Powder X-Ray Diffraction (XRD).  
 
X-Ray Powder Diffraction (XRD) is an analytical technique used for identification of the phases 
of crystalline material formation and provides essential information on the unit cell dimensions of 
such a structure (Afyon et al., 2013). The material to be analysed has to be in powdered form, it is 
then homogenized and its average bulk composition is determined. Max Von Laue discovered. 
This method of crystal analysis in 1912. He noticed that crystalline substances act as three 
dimensional diffraction gratings for X-Ray wavelengths, these were similar to spacing planes 
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LDHs, it has allowed for the proper characterisation and affirmation of the proper structure of the 
LDH and thus we have applied this method to analyse both the MgAl-LDHs as well as the ZnAl-
LDHs.in a crystal lattice structure(Bartholomew, 2013). XRD has been used extensively to 
analyse. 
 2.8.3 Microscopy 
 
Electron Microscopy is an important analytical technique in nanotechnology. Nanoparticles 
generally being small particles (nm scaled) to analyse usually are better characterized using the 
different electron microscopies available. The most common types of electron microscopies 
available are Scanning Electron Microscopy (SEM) as well as Transmition Electron Microscopy 
(TEM). Electron Microscopes apply the principle that because the wavelength of an electron is up 
to 100,000 times shorter than that of visible light photons, the electron microscope is enabled a 
much higher resolving power than a conventional light microscope (Erni et al., 2009). The SEM 
and TEM microscopy techniques were used in the characterisation of the MgAl-LDHs and ZnAl-
LDHs, their calcined derivatives as well as the drug nanohybrids. 
  
2.8.3.1 Scanning Electron Microscopy. 
 
The basic principle of S.E.M is that electrons are accelerated in an SEM and carry large amounts 
of kinetic energy. This energy is dissipated as a variety of signals produced by the electron-sample 
interactions when the incident electrons are decelerated in the sample (Erni et al., 2009). These 
signals include secondary electrons (that produce S.E.M images), backscattered electrons (BSE), 
diffracted backscattered electrons (EBSD that are used to determine crystal structures and 
orientations of minerals), photons (characteristic X-rays that are used for elemental analysis and 
continuum X-rays), visible light (cathodoluminescence–CL), and heat.  The SEM scans the surface 
of the sample giving the profile of its surface morphology, size range, aggregation characteristics 
as well as other essential information about the analysed sample Layered double hydroxides form 
hexagonal or pentagonal structures that can easily be detectable through scanning electron 
microscopy (Swapp, 2016). This information is essential for confirmation of true LDH formation 
after its synthesis and to confirm intercalation of the drug into the respective LDH and monitor 
any morphological and size change. 
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2.8.3.2 Transmission Electron Microscope. 
 
In transmission electron microscopy (TEM), the source of illumination is a beam of electrons of 
very short wavelength, emitted from a tungsten filament at the top of a cylindrical column of about 
2m in height. The whole optical system of the microscope is enclosed in vacuum. Air must be 
evacuated from the column to create a vacuum so that the collision of electrons with air molecules 
and hence the scattering of electrons are avoided. At specific intervals along the column specific 
intervals magnetic coils are placed(Reimer, 2013).  Just as the light is focused by the glass lenses 
in a light microscope, these magnetic coils in the electron microscope focus the electron beam. 
The magnetic coils placed at specific intervals in the column acts as an electromagnetic condenser 
lens system(Reimer, 2013).  TEM was applied in the analysis and imaging of the respective LDHs, 
their calcined version as well as their nanohybrid counterparts. 
 
2.8.4 Nanotracking analysis (NTA)  
 
To truly study a nanoparticle one not only has to look at aspects of surface morphology and 
aggregation properties of a nanoparticle thus another important aspect of our study was the 
colloidal characterization of our LDH nanoparticles and their respective Nanocomplexes (with 5-
Fluorouracil). Being in the range of 35nm to 70nm the LDH exhibits the Brownian motion in 
suspension, governed by both gravity as well as sedimentation. LDHs are fairly stable 
nanoparticles in solution but they have been found to be highly sediment. To fully study the 
colloidal properties of LDHs we employed the use of the Malvern-NS500 Nanosight's 
technology (Choy et al., 2007, Del Hoyo, 2007).  
The Malvern Nanosight NS500 utilizes technology the company termed Nanoparticle Tracking 
Analysis (NTA) which applies the Stokes-Einstein equation for nanoparticle tracking(Malvern, 
2016). Light scattering as well as Brownian motion properties are used to acquire the 
nanoparticle's size distribution and concentration. Using a laser beam that is passed through the 
sample chamber containing the sample in suspension. As the light scatters the nanoparticle is 
visualized through a 20X magnification microscope. As the nanoparticle is bombarded with laser 
beams a camera records and captures a video(Malvern, 2016). To measure the Zeta potential of a 
nanoparticle, an electric field is applied (electrophoretic velocity). This field allows for the 
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movement of the nanoparticles as well as movement of the suspending solution. By measuring 
the total drift velocity composing of both the electrophoresis and electro-osmosis movements the 
zeta potential is measured for a single particle(Malvern, 2016). 
 
2.8.5 Cytotoxicity Studies 
 
2.8.5.1 MTT Assay 
 
To determine the cytotoxic effect of the 5-Fluorouracil after treatment of cells with the drug at 
increased concentrations the MTT Assay was used.  The MTT assay or 3-[4,5-dimethylthiazol-2-
yl]-2,5 diphenyl tetrazolium bromide assay is based on the principle that the MTT reagent is 
converted into formazan crystals by cells which are proliferating, this action which determines 
mitochondrial activity is then used to quantify the amount of cells after treatment, (thus the total 
mitochondrial activity is related to the number of viable cells).  The MTT assay is applied in the 
determination of the in vitro cytotoxic effects of drugs such as anticancer drugs on multiple cell 
lines or primary patient cells (van Meerloo et al., 2011).  NAD(P)H-dependent cellular 
oxidoreductase is an enzyme that is capable of reducing the yellow tetrazolium dye or MTT ( 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide ) to insoluble purple  formazan 
crystals , these formazan crystals are then solubilised with dimethyl sulfoxide (DMSO) which halts 
the reduction reaction (Senthilraja and Kathiresan, 2015).  
  
2.8.5.2 Sulphorhodamine B Assay (SRB). 
  
The Sulphorhodamine B (SRB) assay is a colorimetric assay originally developed by Skehan and 
colleagues to measure drug-induced cytotoxicity and cell proliferation for large-scale drug 
screening applications (Voigt, 2005). This assay is based on the principle that is based on the 
ability of the Sulphorhodamine B protein dye to bind electrostatically and pH dependently on 
protein basic amino acid residues of trichloroacetic acid–fixed cells. Under mild acidic conditions 
it binds to and under mild basic conditions it can be extracted from cells and solubilized for 
measurement (Vichai and Kirtikara, 2006). The Sulphorhodamine B dye or Kiton Red 620 is a 
water soluble fluorescent dye normally used for the quantification of cellular proteins of cultured 
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cells. Using a 96 well plate for this assay, cell monolayers are fixed with trichloroacetic acid (50%) 
and stained for 20 minutes with SRB dye, after which excess dye is washed with 1% acetic acid to 
remove all excess. The protein bound dye is dissolved in 10mM Tris-base and the readings are 
determined using a Microplate reader at 565nm and background absorbance measured at 690nm 
for greater accuracy (Vichai and Kirtikara, 2006) (Coppeta and Rogers, 1998) 
 
2.9 Novelty of study  
 
 
As history has often demonstrated, medicine is a dynamic sector with many improved processes 
being introduced daily. As times change so do the methods often used to combat diseases such as 
cancer. The application of various technologies is helping to provide, more efficient, less costly, 
timeous and non-invasive treatment routes. Nanotechnology is a relatively new approach to 
medicine. Thus, this project looks at the benefits that nanotechnology can provide in the search for 
a treatment for cancer, with the introduction of layered double hydroxides (LDHs) as potential 
nanoparticles for the delivery of chemotherapeutic agents to cancer cells in a safe and controlled 
drug delivery system. This work is cutting-edge and novel not only in a national context but also 
globally. Although previously used to deliver therapeutic nucleic acids such as nucleic acids, 
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To this end, more research is required for the development of efficient delivery systems for these 
drugs, with nanoparticles emerging as a potential strategy for the delivery for many therapeutic 
biomolecules. Thus, our study focuses on designing a drug delivery system capable of delivering 
the broad spectrum drug, 5-fluorouracil (5-Fu). Our study looks at the design and application of 
the MgAl Layered Double Hydroxide nanoparticles (MgAl-LDHs), for the delivery of the 5-Fu in 
vitro.  We synthesized two MgAl-LDHs, namely MgAl 2:1 and MgAl 3:1, containing intercalated 
5-Fu within the gallery, to create nanohybrids, namely, MgAl 2:1-5-Fu and MgAl 3:1-5-Fu. We 
characterized the uncalcined, calcined and nanohybridized MgAl LDHs using XRD, FTIR, ICP-
OES, SEM, TEM, and NTA to confirm synthesis, structural properties, surface morphologies, size 
distribution, stability and zeta potential of these nanoparticles. The synthesis of a true LDH and 
the intercalation of 5-Fu within these nanoparticles was initially confirmed using UV-Vis. 
Percentage encapsulated drug was quantisisied using the encapsulation efficiency formular (%EE).   
A comparative assessment on the effects of the freely delivered 5-Fu versus the LDH delivered 5-
Fu were studied using the MTT and SRB assays in four cell lines, namely human embryonic kidney 
(HEK293), colorectal adenocarcinoma (CaCo-2), breast adenocarcinoma (MCF-7), and the 
hepatocellular carcinoma (HepG2) cell lines, at varied drug concentrations of 12.5 µg/ mL, 25 µg/ 
mL, 50 µg/ mL and 100 µg/ mL. A significant cytotoxicity profile was observed across the four 
cell lines treated with free 5-Fu, with IC50 values ranging between 65.25-92.25 µg/mL. The IC50 
value of the cells treated with LDH encapsulated 5-Fu was lower and ranged from 21.95-36.56 
µg/mL. Nanohybrids were observed to be better tolerated than free 5-Fu in the all cell lines whilst 
eliciting the greatest cytotoxicity in the MCF-7 and CaCo-2 cell lines. 
 
 

















Previously, drug delivery systems (DDS) have focused on the use of organic nanoparticles such 
as lipids and cationic polymers to deliver therapeutic drugs (Kumari et al., 2010).  However these 
systems have proven to be poor drug delivery vehicles, due to their inability to provide a stable 
encapsulating environment in which the drug is protected against physiological parameters in the 
body (Wilczewska et al., 2012).  Even when these organic DDSs were co-synthesized with other 
moieties to form ligand based delivery systems, they were still unstable leading to their 
disintegration and subsequent premature drug release (Hofheinz et al., 2005). This has led to the 
introduction of inorganic nanoparticles which has the potential to overcome some of the shortfalls 
of previously employed nanoparticles. From the array of nanoparticles utilised in 
chemotherapeutics today, MgAl-LDHs are slowly showing the ability to be an efficient vehicle 
for delivery (Ladewig et al., 2010, Xu et al., 2006). The structurally simple and one of the most 
abundant LDHs available, MgAl-LDH, has being used for the delivery of anticancer drugs such 
as methotrexate (MTX) (Baldo and Pagani, 2014), 5-fluorouracil (5-Fu) (Choi et al., 2008, 
Longley et al., 2003), doxorubicin (DOX) among others (Gunawan and Xu, 2008).  
 
This LDH has been used previously in the pharmaceutical industry as components in deodorant 
sprays, antacids (Newton et al., 2008), antiseptic agents (Katheria et al., 2016) and commercial 
products such as Talcid® and Bemolan® (Del Arco et al., 2004). Their good adsorbent properties 
have also made them suitable for the adsorption of intestinal phosphates (Gunawan and Xu, 2008). 
Some of the advantages of using this LDH include low to negligible toxicity, ease and low cost of 
preparation, ability to customize their physicochemical properties, anion exchange capacity, and 
weathering reactions as observed at lowered pHs, which allow for targeting of cancer cells 
(Gatenby and Gillies, 2004). The lowered pH of cancerous cells is due to the high rate of aerobic 
glycolysis. This is advantageous for the LDH as it enables slow drug release in the cancerous cells 
without harming healthy and pH balanced cells (Gatenby and Gillies, 2004). These nanoparticles 
largely resemble the brucite structure with the chemical formula Mg (OH) 2, and were among the 















−) x/m·nH2O] (x = 0.2–0.4; n = 0.5–1), where M
II
 
represents magnesium (Mg2+ ) and MIII represents aluminium ( Al 3+ ), Am would be the anionic species 
and although there is a wide range of x values to describe the MgAl-LDH structure, pure MgAl-LDHs 
are usually limited to the range of 0.2 ≤ x ≤0.3. MgAl LDHs have also been applied in industrial 
settings as, absorbents for toxic chemicals, stable and recyclable heterogeneous catalysts, as well as in 
other essential industrial applications (Fan et al., 2014). The successful delivery of MTX and 5-Fu to 
cancer cells using the MgAl-LDH has been reported (Choi et al., 2008). Furthermore, their enhanced 
cellular uptake and improved drug efficacy compared to free MTX or 5-Fu have been confirmed (Kim 
et al., 2014). The co-delivery of 5-Fu and MTX with MgAl-LDH, leading to effective cancer cell death 
was also reported (Choi and Choy, 2011, Choi et al., 2008); (Kim et al., 2014). MgAl-LDH loaded 5-
Fu and PI3K/mTOR dual inhibitor (BEZ-235) was able to produce effective inhibition of colon 
cancer cells utilizing the apoptotic pathways, with reduced cytotoxic effects observed with the co-
delivery of 5-fluorouracil in colon cancer, HCT-116 cell. BEZ-235 was also introduced as a 
potential inhibitor of the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway which 








Sodium carbonate (NaCO3), sodium hydroxide (NaOH), HCl, MTT reagent, dimethylsulfoxide 
(DMSO), phosphate buffered saline (PBS) tablets, trichloroacetic acid (TCA), acetic acid and 
Tris EDTA were purchased from Merck, Darmstadt, Germany. Aluminium nitrate, Al (NO3)3. 
9H20, was obtained from C.C. Imelmann, Southdale, South Africa, and magnesium nitrate, Mg 
(NO3 )2 .6H 2O from Holpro Analytic (PTY) LTD, Krugersdorp, South Africa. The anticancer 
drug, 5-fluorouracil (5-Fu) and sulphorhodamine B (SRB) were purchased from Sigma-Aldrich, 
St Louis, USA. Eagles Minimum Essential Medium (EMEM), Penicillin/ Streptomycin, and 
Trypsin-versene were all obtained from Lonza Biowhittaker, Walkersville, USA. Fetal bovine 




Human embryonic kidney cells were provided by the Anti-viral gene therapy unit, Medical 
School, University of the Witwatersrand, South Africa. Human hepatocellular carcinoma, breast 
adenocarcinoma and colorectal cancer cells were purchased from Highveld Biological (PTY) 
LTD., Lyndhurst, South Africa. All sterile tissue culture plasticware was obtained from Corning, 






3.3.1 Synthesis of the MgAl layered double hydroxides 
 
LDHs were synthesized using the co-precipitation method. Approximately 25,6 g of 0.1 M Mg 
(NO3 )2. 6H2O and 18.7g of 0.05M Al(NO3)3 .9H2 O for (MgAl 2:1), and 25.6 g 0.1 M Mg (NO3 
)2 .6H2O and 12.8g of 0.05M Al(NO3)3 .9H2O for (MgAl3:1) were dissolved separately in 150 ml 
of distilled 18 M water. Na2CO3 (53 g) was then dissolved in 600 ml of distilled water with 
stirring at 720 rpm at room temperature. This was then titrated to pH~11 with Al (NO3)3 · 9H2O 
and Mg(NO3)2·6H2O using NaOH for pH adjustments. The mixtures were aged overnight at 80 
C, and then washed again with 18 MΩ water. The slurries were first vacuum dried and placed 
overnight in an oven at 110 ºC. The LDHs were then crushed to a talc-textured powder and stored 







The synthesis of the nanocomplexes composed of the MgAl LDHs and the anticancer drug, 5-Fu 
involved the calcination of the LDH to form mixed metal oxides before complexation. This phase 
transition assists in a smoother intercalation of 5-Fu into its host during the complexation process. 
Simultaneously, the LDH structure is completely recovered due to its “memory effect” with 
addition of the solution containing the 5-Fu. In a typical calcination procedure, 50 mg of the 
synthesized MgAl-LDH (MgAl- 2:1 and 3:1, respectively) were placed in a horizontal furnace 
(Labofern PUB002) set at 400 
°
C and maintained at this temperature for 8 hours under N2. After 
calcination, each of the samples were labelled and stored in a glass bottle for later use. 
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3.3.3 MgAl-LDH: 5-Fu conjugate synthesis 
 
 
To intercalate 5-Fu into both the MgAl-LDHs (2:1 and 3:1 respectively) the reconstruction 
method was used. Approximately, 11.1 mg of the calcined MgAl LDH powders were suspended 
in 20 mL (diluted with distilled water) of 5-Fu (0.0114 M in 18 M water, pH 8.0) solution (5-
Fu alkalized with 0.1M NaOH). The mixture was then vigorously stirred under N2 atmosphere 
for 24 hours at room temperature to obtain the MgAl-LDH-5-Fu conjugates for both LDHs. The 




3.3.4 Drug encapsulation efficiency 
 
 
The drug encapsulation efficiency study was conducted to determine how much of the drug was 
actually encapsulated or bound to the respective LDHs. The respective LDH-5-Fu suspensions 
were centrifuged at 12000 rpm for 5 minutes, and the supernatants assayed by UV-Vis 
spectroscopy (Biomate, Thermoscientific) for presence of free 5-Fu. The pellets were then 
resuspended and readings were taken again to measure absorbance of bound drug. Readings were 
taken at 266 nm and the results were calculated using the formula: 
 
 




3.3.5 Powder X-Ray diffraction 
 
  
Powder X-Ray diffraction (XRD) was performed for the uncalcined (pure), calcined and drug 
conjugated MgAl LDHs. The analysis was carried out using a Bruker D8 Advanced XRD 
analyzer (CuKa radiation) equipped with Bruker analysis software. In each of the runs, 0.5 g of 










3.3.6 Fourier Transform Infrared Spectroscopy (FTIR) 
 
 
Infra-red (IR) spectra of the LDH and nanocomplexes were obtained with a Perkin Elmer FTIR 
Spectrometer equipped with a Universal ATR sampling accessory using a diamond crystal. 
Spectrum Analysis Software was used for analysis of the data. 
 
3.3.7 Inductively Coupled Plasma Analysis-Optical Emission Spectroscopy (ICP-OES) 
 
 
Elemental detection and quantification of metal content of the LDH and its complexes were 
obtained by inductively coupled plasma-optical emission spectroscopy (ICP-OES), performed on 
a Perkin Elmer Optima 5300 DV Optical Emission Spectrometer. Standard calibration curves were 
set up between 1 and 20 ppm, using 100 ppm standard stock solutions of the respective metal 




3.3.8 Electron Microscopy 
 
 
Electron microscopy (EM) was used to confirm the morphologies, structural orientation and the 
general surface anatomy of the pristine (i) MgAl-LDHs along with their calcined derivatives and 
 
(ii) MgAl-LDH-5-Fu conjugates (2:1 and 3:1). Scanning Electron Microscopy (SEM) using 0.1 
mg samples was carried out using a ZEISS LEO 1450 scanning electron microscope. 
Transmission Electron Microscopy (TEM), using 1µl of each sample, was done in a JOEL1010 
electron microscope fitted with Megaview 3 soft imaging system and images were viewed using 




3.3.9 Nanoparticle Tracking Analysis (NTA) 
  
 
The nanosight NTA NS500 (Malvern Instruments Ltd, Worcestershire, United Kingdom) was used 
to visualize and analyse the pristine and drug conjugated samples. NTA analyses the sample’s size 
and zeta potential by tracking the rate of the Brownian motion to the particle's size. The samples 
were diluted to approximately 0.1 mg/mL in deionized 18 M water. All measurements were 
acquired at 25 C. To eliminate the risk of indiscrepencies in the results, the instrument was 




3.3.10 Drug release Studies 
 
 
Drug release studies were performed by dialysis as described by (Maghsoudi et al., 2008). 
Briefly, 1 mL of the MgAl-5-Fu solutions (2:1 and 3:1 respectively) were dialyzed (MWCO ~ 
7000 KDa), against 20 mL of phosphate buffered saline PBS (pH 4 and pH 7) under constant 
stirring for 7 hours. Aliquots of 1 ml from the PBS solution were removed for UV-Vis analysis 




3.3.11 In vitro cell culture studies 
 
 
All cell culture studies were conducted under sterile conditions. Cell growth and morphology were 
constantly monitored using an inverted microscope (Nikon TMS F 6V, Tokyo, Japan). Growth 
medium in cells were replenished when required, and cells were routinely split at or near 
confluency into sterile cell culture flasks to prevent overgrowth and keep the cells in the log phase. 
For cell culture assays, cells were counted using an haemocytometer and plated into either 96 or 




3.3.12 MTT Cytotoxicity assay 
 
 
Cell toxicity of the free drug and LDH encapsulated drug was evaluated using the four mammalian 
cell lines: CaCo-2, HepG2, MCF-7 and HEK293. Cells were seeded into 96-well plates at a density 
of 1 × 10
4
 cells/well in 100 μL of complete medium (EMEM +10% FBS + antibiotics) and 
incubated overnight at 37 C in a humidified CO2 incubator. Following incubation, cells were 
treated with the drug alone and MgAl encapsulated drug at increased concentrations (12.5 µg/ mL, 
25 µg/ mL, 50 µg/ mL and 100 µg/ mL), and incubated for 48 hours. Thereafter, the medium was 
removed and 100 µL of MTT reagent and 100 µL of medium was added to the cells, which were 
then incubated for a further 4 hours at 37 ºC. The MTT infused medium was then removed and 
100 µL of DMSO was added to the cells to dissolve the formazan crystals produced.  
The coloured solutions were then read using a MR-96A microplate reader (Vacutec, Hamburg, 
Germany) at wavelength of 570 nm, with 650 nm being used for reading.
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 The assay was conducted in triplicate (n=3), and percentage cell viability was calculated using the 
following formula:  
 




3.3.13 Sulphorhodamine B (SRB) Cytotoxicity assay 
 
 
Cells were seeded and treated as in 3.3.12. After the 48-hour incubation at 37 ºC, cells were fixed by 
gently layering with ¼ volume of cold 50% TCA on top of the growth medium and incubated for an 
hour at 4 ºC. Cells were then rinsed with deionized water to remove the TCA and other serum proteins. 
After air-drying, 50 µL of 0.4 % SRB solution was added to the cells for 20 minutes. Thereafter, the 
cells were washed with a 1% acetic acid solution.  
To solubilize the dye, 100 µL of a 10 mM Tris-EDTA solution was added and the plate rocked gently 
on a platform shaker (Stuart Scientific, STR 6) for 5 minutes. Absorbance was then read in a 







Apoptosis studies were carried out using the dual-staining acridine orange and ethidium bromide 
(AO/EB) method to compare the effects of exposure of the cells to “free” 5-Fu and MgAl-LDH-5-
Fu. Approximately, 100 mg/mLof both dyes (1:1 ratio) were prepared in sterile PBS. Cells at 
confluency were plated into 24 well plates at a seeding density of 1.2 x 10
5
 cells/well, incubated for 
24 hours at 37 C, and then treated with free and MgAl encapsulated drug (20 µL) for 48 hours.  
Thereafter, cells were washed with 100 µL PBS, and 15 µl of the dual stain was added and cells kept 
at room temperature for 5 minutes. These cells were then visualized using an Olympus fluorescent 
microscope at X200 magnification, following which apoptotic indexes were calculated using the 
described formula: 
 
Apoptotic Index = Number of apoptotic cells 









    
3.3.15 Statistical analyses 
 
 
All statistical analyses were performed using Graph pad prism 5.0 (GraphPad Software, Inc., San 
Diego, CA), one-way analysis of variance (ANOVA). Differences between groups were considered 




3.4 Results and Discussion 
 
3.4.1 Syntheses of LDHs 
 
We successfully synthesised MgAl-LDHs (2:1 and 3:1) through the co-precipitation method, yielding 
1.18 g and 1.33 g, respectively. The talcum textured LDH powders were pristinely white and had no 
visible contaminants (Figure 3.1). There was a measureable loss in the mass of the LDHs after 
calcination, so that 0.56 g and 0.60 g of the MgAl 2:1 and MgAl 3:1 LDHs respectively. This is due 
to the processes of dehydration, dihydroxylation, and decarbonation that the LDHs undergo during 





















   
 
 












    
3.4.2 UV-Vis spectroscopy. 
  
 
UV-Vis spectroscopy was employed to determine the binding or encapsulation efficiency 
percentages of the drug-loaded LDHs (Figure 3.2, Table 3.1). The calcination method 
incorporates the drug as the LDH is being resynthesized after exposure to drug solution, however 
the structure may be compromised, thus affecting the encapsulation efficiency of the LDH (Zhang 
et al., 2006). Overall the encapsulation efficiency of 5-Fu was above 40 %, with 58.94 % and 


























































Figure 3.2 UV-Vis spectoscopy of 5-Fu, MgAl 2:1-5-Fu and MgAl 3:1 5-Fu 
 
 
Table 3.1: MgAl-LDHs Encapsulation Efficiencies (% EE) 
 
LDH Nanohybrid formula Encapsulation Efficiency (%EE) 
   
MgAl 2:1 MgAl 2:1-5-Fu 58.94 
   
MgAl 3:1 MgAl 3:1-5-Fu 42.85 










3.4.3 Powder X-ray Diffraction Spectroscopy. 
   
We further confirmed the synthesis, calcination, as well as reconstitution of the structure of the 
LDHs utilizing XRD spectroscopy (Appendix A.1).  The synthesized LDHs, showed the 
characteristic (003) peak approximately around 2-theta 14.50 ⁰ for pristine MgAl 2:1 and at 
approximately 2-theta 13.00 o for pristine MgAl 3:1. These peaks may correspond to the d-spacing 
of 0.75 nm due to the carbonate within this gallery space, which were both lost after calcination 
of the respective MgAl-LDHs, as a result of decarboxylation and dehydration reactions. Our 
findings confirm thinning of the gallery space as well as loss of the 'house-of cards' lattice of the 
LDHs. A shift was observed in the peaks for both MgAl 2:1-5-Fu and MgAl 3:1-5-Fu. These clear 
shift indicate the possible change in the dimension of the gallery space due to an intercalation of 
an anionic molecule, which in this case is the 5-Fu. The reconstituted structure, although shows 
good intercalation of 5-Fu, also indicates structural compromise. Thi9s could be due to the partial 





3.4.4 Fourier Transform Infrared Spectroscopy 
 
 
Fourier Transform Infrared spectroscopies were performed and also confirmed the presence of the 
5-Fu molecules in the respective MgAl-LDHs (Appendix A.2).  Comparative IR readings of the 
pristine MgAl 2:1 LDH and the MgAl 3:1 indicated characteristic hydroxyl groups around 
3000cm-1 for both LDHs.  The strong absorption bands within the range of 1500cm
−1
 can be 
attributed to the multi-substituted 5-fluorouracil in both the LDHs.  For both LDHs, bands were 
also observed at the lower-frequency region, due to the vibration of M-O and M-O-M (M=Mg, 
Al) at their various atomic ratios. These lattice vibrations were observed around 500 cm
-1














3.4.5 Inductively coupled plasma-optical emission spectroscopy (ICP-OES) 
   
Inductively coupled plasma-optical emission spectroscopy (ICP-OES) was performed on the 
MgAl-LDHs (2:1 and 3:1) and their nanohybrids confirmed the presence of magnesium and 
aluminium in their appropriate ratios. The nanohybrids also confirmed presence of 5-Fu within the 




3.4.6 Electron Microscopy (TEM and SEM) 
 
TEM and SEM microscopies were performed for the characterisation of the respective MgAl-
LDHs (MgAl 2:1and 3:1), their calcined derivatives as well as the resulting nanohybrids after 
reconstruction. Significant differences were noted between the two MgAl-LDHs. Pristine MgAl-
LDH 2:1 (Figure 3.3) showed a more defined structure with more defined edges and a clearly 
anisotropic shape compared to the MgAl-LDH 3:1 under TEM (Figure 3.4). This observation 
was further clarified with SEM imaging (Figure 3.5). This was also the case for MgAl 2:1 It has 
been previously reported that the difference in surface structure of LDHs of the same type 
(however differing elemental compositions) is due to active surface atoms, with LDHs generally 
aggregating during storage and application (Kuang et al., 2010). The lateral size and thickness 
of MgAl 3:1, nanohybrid before and after calcination as well as after reconstruction was 
observed again with SEM (Figure 3.6). 
 
MgAl 2:1 changed in lateral size and thickness after calcination, from an average of ~70 nm ±15 
before calcination to ~58 nm ±12 after calcination, while MgAl 3:1 changed from ~60 nm ±16 to 
~55 nm ±14, respectively. Calcination topochemically decomposes the LDH due to water loss in 
the gallery space, resulting in a decrease of the gallery space (d value). However, it was discovered 
that after exposure to the drug solution, the LDH recovered its characteristic hexagonal shape, as 
seen with the increase in lateral size and thickness to an average size of ~68 nm ± 14. Overall, 
electron microscopy confirmed the intricate “house-of-cards” structure characteristic of the LDHs, 
due to the enhanced particle-edge interaction, which was recovered after reconstruction. 





that reveals that aggregation and distribution characteristics vary to a great degree, due to the 
method of synthesis. 
                                                                                                                                                 
 
 
 Figure 3.3 TEM images of (a) MgAl 2:1, (b) Calcined MgAl 2:1 (c) and MgAl 2:1-5-Fu (Bar =200 nm). 








Figure 3.5 SEM micrographs of (a) MgAl 2:1 pure (b) calcined MgAl 2:1 (c) MgAl 2:1-5-Fu 
(scale bar </=100nm). 
(a)                                (b)                                         (c) 
)  
(a)                               (b)                                         (c) 
)  













3.4.6 Nanoparticle Tracking Analysis (NTA) 
 
 
NTA was performed to accurately determine nanoparticle size distribution and zeta potential 
(Table 3.2, Appendix A.3). It was observed that the pristine LDHs had a tendency to aggregate 
much further in solution. However, we noted very slight changes in the size of the nanohybrids 
(138 -140 nm for MgAl 2:1 and MgAl 2:1-5-Fu; and 179.9 to 178 nm for MgAl 3:1 and MgAl 
3:1-5-Fu respectively). This could possibly be due to the effects of calcination and reconstruction 
with 5-Fu. Importantly, all sizes were below 200 nm, an important cut off for in vitro cellular 
uptake. Zeta potential values observed were in accordance with previous reported research (Choi 
and Choy, 2011). The LDH nanoparticle are composed of the cationic layers that dominate the 
outer space of the nanoparticle (Kim et al., 2014). The interesting twist we observed was that the 
nanohybrid MgAl 2:1-5-Fu displayed a slightly negative zeta potential (-37.3 mV), this could 
largely be influenced by the effects of the nanoparticles calcination and subsequent encapsulation 
of 5-Fu rendering an ion exchange within the gallery space. Overall the MgAl 3:1 (31 mV) and 






















Table 3.2: Size and zeta potential of MgAl 2:1. MgA 2:1-5-Fu, MgAl 3:1 and MgAl 3:1-5-Fu 
 
PROPERTY  LDH SAMPLE  
     
Sample name MgAl 2:1 MgAl 2:1-5-Fu MgAl 3:1 MgAl 3:1-5-Fu 
     
Size (nm) 138 2.1 140 2.1 179.9 2.1 178.1  0.2 
     
Zeta Potential (mV) 108 8.8 -37.3  0.22 31.00.2 32.2 0.1 
     
 
 
Importantly, the higher the zeta potential values (irrespective whether they are positive or 
negative), the greater the mobility of the nanoparticles, and the better the colloidal stability, which 
favours cellular uptake and internalisation, and reduces aggregation effects. This also bodes well 
for systemic delivery. Based on this the MgAl 3:1-5-Fu (32.20.1 mV), seem to have the most 






3.4.7 Drug release studies 
 
 
It has been previously reported that 5-Fu released from various LDHs retained it pharmacological 
activity. Thus, we hypothesise that due to LDH’s disintegration pattern at lower pHs, 5-Fu could 
also be easily and controllably released from the LDHs. Hence, pH dependent drug release studies 
somewhat confirmed the MgAl-LDHs’ a pattern of drug release at the different pHs. MgAl 2:1-
5-Fu showed release of the drug, but rather very slowly in comparison to the drug release at pH 4 
at pH~ 7, over the 7-hour period after an initial burst release from t=0 to t=1. At pH~ 4, the drug 
was initially released quicker than at the neutral pH (Figure 3.7a).  At pH=4, 80 % of the drug had 
been released from the MgAl 2:1-LDH over the time period tested. A similar profile was observed 
for MgAl 3:1-5-Fu (Figure 3.7b) from t=0 to t=6. However the release was slower and could be 
due to better structural recovery after reconstitution.  Approximately, 60 % of the drug had been 
released at t=7. These results however show that due to the lowered pH of cancerous cells the 
drug could be released gradually within cells offering maximum effect of the drug.  
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Furthermore, the endosomal compartments which generally pose a barrier in intracellular 





Figure 3.7: Drug release profiles of MgAl 2:1-5-Fu (a) and MgAl 3:1-5-Fu (b) at pH ~4 and pH ~7 
respectively. 
 
3.4.8 Cytotoxicity studies. 
 
3.4.8.1 MTT assay 
 
 
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay was used to 
determine the cytotoxic effect of the 5-Fu after treatment of cells with the drug at increased 
concentrations on the four cell lines, HEK293, MCF-7, Hep-G-2 and CaCo-2 cell lines. This assay 
is based on the principle that the MTT reagent is converted into formazan crystals by mitochondrial 
reductases in viable cells. It hence determines mitochondrial activity and can be used to quantify 
the amount of viable cells after treatment.   From Figures 3.8-3.9, it is evident that the unbound /free 
5-Fu resulted in a greater cell death of all cell lines, which is further confirmed by the IC50 values 
calculated (Table 3.3). The IC50 values ranged from 22.18-36.56 µg/mL for the cells exposed to free 
5-Fu, but were slightly higher for the MgAl 2:1-5-Fu (82.25-92.25 µg/mL) (Figure 3.6) at the same 
drug concentration. A similar pattern was observed for the cells exposed to MgAl-3:1-5-Fu and free 
5-Fu again (Figure 3.9), with IC50 values ranging from 65.25 -72.25 µg/mL and 21.25-28.57 µg/mL 
respectively, at the same concentrations. This high cell death with free 5-Fu could be due to the 
































































    
the cell. However, a gradual cell death profile correlating with increased LDH-5-Fu concentrations 
in all cell lines was observed, which could be due to the slow controlled release of the drug from 
the LDHs leading to gradual uptake by the cells. Hence, there is gradual but significant cytotoxicity 
effect in the cells as the drug is released in smaller doses over a period of time.  
The MgAl-LDH-5-Fu nanohybrids did not show any particular cell specificity, but an overall 
lower level of cytotoxicity in the HEK293 cells was noted for the MgAl 2:1-5-Fu complexes 
only. The HEK293 cell line has an intracellular pH of 7.3 (Stoop et al., 1997), which could offer 
slight protection to this cell line. LDHs will only release the encapsulated contents at low pHs 
and preferably in acidic environments, as the case is for almost all cancerous cell lines. Although 
a degree of cytotoxicity was seen across all cell lines, it is worth noting that MgAl-LDH elicited 
a greater cytotoxic effect on the HepG2 cell line followed by the CaCo-2 cell line (Figure 3.9, 
where the rate of cell death is indicated across all cell lines against the controls, i.e untreated 
cells (cntrl cell) and cells treated only with LDH (cntrl LDH)).  
The increased cell death for the CaCo-2 cell line may also be attributed to their slightly higher 




Figure 3.9: MTT Assay with MgAl-2:1-5-Fu and free 5-Fu at concentrations 12.5 µg/mL, 25 µg/mL, 
50 µg/mL and 100µg/ mL on HEK293, MCF-7, HepG2 and CaCo-2 cell lines [data presented as 
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Figure 3.10: MTT assay with MgAl-3:1-5-Fu and free 5-Fu at concentrations 12.5 µg/mL, 25 µg/mL, 50 
µg/mL and 100 µg/mL), in HEK293, MCF-7, HepG2 and CaCo-2 cell lines against [data presented as 
means SD(n=3) (*p<0.05; **p<0.01). 
 
Table 3.3: IC50 (µg/mL) values for MgAl 2:1-5-Fu, MgAl 3:1-5-Fu versus free 5-Fu (respectively). 
 
Cell line MgAl 2:1-5-Fu Free 5-Fu MgAl 3:1-5-Fu Free 5-Fu 
     
     
HEK293 92.25 22.18 65.25 21.95 
MCF-7 90 35.25 73.95 35.25 
HepG2 82.25 36.00 79.75 30.69 
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3.4.8.2 Sulphorhodamine B (SRB) assay 
 
 
The Sulphorhodamine B (SRB) assay is a colorimetric assay used to measure drug-induced 
cytotoxicity and cell proliferation for large-scale drug screening applications (Voigt, 2005). This 
assay is based on the ability of the Sulphorhodamine B protein dye to bind electrostatically and pH 
dependently basic amino acid residues in TCA–fixed cells. It binds to cells under mild acidic 
conditions can be extracted from cells under mild basic conditions, and solubilized for     
measurement (Vichai and Kirtikara, 2006). The SRB assay cytotoxicity findings correlated with 
those of the MTT assay results. A similar cytotoxicity profile was observed in all cells with free 5-
Fu and LDH-loaded nanohybrids (Figures 3.11-3.12). Herein, we also noticed no significant cell 




Figure 3.11: SRB assay for MgAl-2:1-5-Fu and free 5-Fu at 12.5 µg/mL, 25µg/mL, 50µg/ mL and 100 
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Figure 3.12: SRB assay of MgAl-3:1-5-Fu and free 5-Fu at 12, 5 µg/mL, 25 µg/mL, 50 µg/mL and 100 




Table 3.4: IC50 (µg/mL) values for MgAl 2:1-5-Fu, MgAl 3:1-5-Fu versus Free 5-Fu respectively. 
 
Cell line MgAl 2:1-5-Fu Free 5-Fu MgAl 3:1-5-Fu Free 5-Fu 
     
  IC50 values in µg/mL  
HEK293 67.25 22.95 77.25 18.25 
MCF-7 63.69 30.25 76.69 20.75 
HepG2 77.25 31.19 80.25 28.19 
CaCo-2 72.25 21.87 82.19 41.07 
 
 
3.4.9 Apoptosis studies 
 
 
Apoptosis studies were performed using the dual staining acridine orange and ethidium bromide 
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studies showed a more controlled apoptotic pattern (Figure 3.13 and 3.14). Apoptotic indexes were 
calculated to determine the impact of the LDH delivered drug against the freely delivered drug and 
these are tabulated in Table 3.5.  
Overall, the drug loaded LDHs produced lower apoptotic indices compared to the free drug. The 
apoptotic cells appear red, with live cells appearing green. From the images it can be seen that there 
was greater apoptotic induction by the 5-Fu in all cell lines, with drug loaded LDHs produced high 
apoptosis in the HepG2 and CaCo-2 cell line. Using the dual staining method, live cells (L) usually 
appear green, early apoptotic cells appear yellow (EA), late apoptotic cells are orange and apoptotic 
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Figure 3.13: Fluorescent images of apoptosis induced by (A) MgAl 2:1-5-Fu and free 5-Fu, in 
HEK293, MCF-7, HepG2 and CaCo-2 cell lines (L=Live cells, A=Apoptotic cells, LA= Late Apoptotic 
cells and EA= Early Apoptotic cells). 
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Figure 3.14: Fluorescent images of apoptosis induced by (A) MgAl 3:1-5-Fu and free 5-Fu, in 
HEK293, MCF-7, HepG2 and CaCo-2 cell lines (L=Live cells, A=Apoptotic cells, LA= Late Apoptotic 
































Table 3.5: Apoptotic Index (AI) of cells exposed to MgAL-2:1-5-Fu, MgAl 3:1-5-Fu and free 5-Fu 
 
  APOPTOTIC INDEX (AI)   
Cell lines Control Control MgAl 2:1- Free 5-Fu MgAl 3:1- Free 5-Fu 
 Cell LDH 5-Fu  5-Fu  
HEK293 0.00 0.00 0.1 0.25 0.02 0.05 
MCF-7 0.00 0.00 0.15 0.111 0.09 0.210 
HepG2 0.00 0.00 0.1 1 0.1 1.15 










Layered double hydroxides are perhaps the most intricate, sophisticated yet simple nanoparticles, 
and their ability to intercalate and protect biomolecules comes as a huge scientific advantage. 
MgAl LDHs can prove to be potentially beneficial nanoparticles in the challenging process of 
chemotherapy. In this study we have discovered that the structure of the LDH plays a vital role in 
the encapsulation of 5-Fu. The intercalation property of LDHs offers a degree of control over the 
amount of drug encapsulated and released. Drug encapsulation efficiency was above 40 %, with a 
maximum drug release of 80 % occurring in a controlled manner over a 7-hour period. Cytotoxicity 
studies showed that these LDHs had a dose-dependent profile in the four cell lines tested. However, 
it is interesting to note that the level of cytotoxicity was higher for cells treated with free 5-Fu, 
which was further confirmed by the fluorescent apoptosis assay, which showed that greater 
apoptosis was induced by the drug alone than the LDH bound drug as evidenced by its’ higher 
apoptotic index. 
 
The LDHs furthermore did not show significant cell specificity, although they had a dose 
dependent reaction with gradual cell death. This profile added to the notion that these LDHs were 
able to slowly release the drug over time, bodes well for their in vivo use. The ability of LDHs to 
disintegrate at acidic pH, is another advantageous feature, which ensures that the acidic 
environment of cancerous cells will be favourable for the release of therapeutic contents. 
Although the intercalation of species within the LDHs is a rapid process, their deintercalation is 
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not. Very low pH levels are required for the nanoparticle to fully disintegrate as observed in the 
pH-dependent drug release studies. 5-Fu is an anticancer drug predominantly used to treat colon-
cancers, and 5-Fu loaded LDHs may be suitable for the oral administration of 5-Fu with further 
optimizations. The LDH property of drug release at a lower pH would be beneficial in this case, 
where pH is below 6. Overall, this study has shown the potential of MgAl-LDHs as promising 
drug delivery systems.  Future studies and recommendations include testing the release profile 
over a longer time period, increasing the steric stability of the LDHs, using a polymer such as 
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THE APPLICATION OF ZnAl-LDHs AS POTENTIAL ANTICANCER 
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Inorganic-based delivery systems have attracted attention especially due to their relative inertness, 
allowing for safe and stable delivery of macromolecules in biological systems, and their ability to be 
easily manipulated. ZnAl-LDH layered double hydroxides (LDHs) have long been utilized to deliver 
anti-inflammatory drugs as well as antibiotics. In this study we successfully synthesized two 5-
Fluororuacil (5-Fu) delivery systems, namely, ZnAl 2:1-5-Fu and ZnAl 3:1-5-Fu, from the pristine 
LDHs ZnAl 2:1 and ZnAl 3:1 using a reconstruction technique. All LDHs and conjugates were 
characterized using SEM, TEM, XRD, FTIR, ICP-OES and NTA. Encapsulation efficiencies (%EE) 
of the nanoparticles were above 50 % for both ZnAl 2:1-5-Fu (64.92 %) and the ZnAl 3:1-5-Fu (56.56 
%) nanohybrids. Drug release profiles revealed a steady and gradual release of 5-Fu from the gallery 
space of the respective ZnAl-LDH the ZnAl 3:1-5-Fu nanohybrid 89 % of drug after 7 hours. In vitro 
studies were carried out to determine the cytotoxicity conferred by the LDH-encapsulated and the free 
drug at the same concentrations on four human cell lines, embryonic kidney (HEK293), breast 
adenocarcinoma (MCF-7), hepatocellular carcinoma (HepG2) and colorectal adenocarcinoma (CaCo-
2). The MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 
sulphorhodamine B assays (SRB) cytotoxicity assays, demonstrated higher cell death for free 5-Fu 
treated cells. The HEK293 cells through the virtue of their neutral intracellular pH were affected to a 
lesser degree. The ZnAl-LDHs were most effective at conferring controlled cell death on the MCF-7 
and CaCo-2 cell lines, although a considerable cell death was observed. The LDHs offered a more 
controlled system of drug delivery than the freely delivered 5-Fu as was seen with IC50 ranging from 
41-54 (free 5-Fu) and high IC50s at 
65.50-77.05(ZnAl-LDH) encapsulated 5-Fu. Apoptosis studies conducted, confirmed that much 

















Cancer is a global chronic disease and is fast becoming a lead cause of mortality, despite the vast 
array of cancer therapeutics available. Chemotherapy is the common technique for cancer therapy, 
but comes with significant side-effects, and the need for repeated treatments which does not 
guarantee the remediation of the cancer. Most conventional drug delivery systems (DDS) have 
shortfalls such as poor oral bioavailability, low therapeutic indices, lack of water solubility, 
nonspecific biodistribution and targeting (Allen and Cullis, 2004, Cho et al., 2008, O'hare, 2014). 
It is for these reasons, the field of nanomedicine has evolved, using nanotechnology for the 
designing of new methods for cancer therapy.  Thus researchers are currently looking into the 
application of nanotechnology in solving the problem of the lack of effective and inexpensive DDS 
(Cho et al., 2008). Nanotechnology is on the verge of becoming one of the breakthroughs, 
presenting the potential for the development of nanoparticles that could be used as delivery 
vehicles for these therapeutic drugs (Kompella, 2013, Liu et al., 2012). Among the nanoparticles 
currently being researched, LDHs, are proving to be promising due to their structural uniqueness 
and versatile surface topography (Choy et al., 2007, Rives et al., 2014, Wang et al., 2015). LDHs 
are composed of a two dimensional structural network composed of different hydroxy layers of 
divalent and trivalent metal ions in determined ratios (Mandal and Mayadevi, 2008, Manzi-Nshuti 
et al., 2009). Isomorphic substitution of some divalent metal ions of LDHs with trivalent ions, 
gives rise to a positive residual charge in the structure, which is counterbalanced with anions and 
water molecules located interstitially (Mandal and Mayadevi, 2008). LDHs are defined by the 






, abbreviated as [MIIM III − X], where M 
II




 = Al3+, Fe3+, Cr 3+ and X
−
 = CO3 2−, Cl 2
−, NO 3+ (Chen et al., 2014a, 
He et al., 2006, Pérez et al., 2006, Perioli et al., 2011), with a molar ratio in the range of 0.2 to 
0.4. The ordering of the cations affects the charge density of the LDH sheets, which is the main 
reason why LDHs have a tendency to have a high positive charge (Ma et al., 2006). This factor 
has consequences for a variety of physicochemical parameters, such as bonding, reactivity, 
orientation, and mobility of the chemical species in the interlayer gallery and on the surface (Bi et 
al., 2014b). Previously LDHs have been used in ceramic development (Evans and Duan, 2006), 
water purification (Goh et al., 2008), toxic waste removal (Choy et al., 2007) .
 In this study, we present ZnAl-LDHs as potential anticancer drug delivery vehicles. This type of 
LDH is no stranger to chemotherapy as it has been previously employed in the delivery of also 





Oh et al., 2009). ZnAl have been intercalated with drugs such as diclofenac (DIK), a non-steroidal 
anti-inflammatory drug (Perioli et al., 2011). The application of LDHs as novel antibacterial drug 
delivery systems, with intercalated cefazolin have also been reported. LDHs are suitable 
nanoparticles to be used in drug delivery as they are (i) conveniently synthesized, (ii) offer 
structural manipulation, (iii) morphological tenability, (iv) low in toxicity and (v) biocompatible 








Zinc nitrate [Zn(NO3)2 .6H2O (0.1 M)], trichloroacetic acid (TCA), sodium hydroxide (NaOH), 
sodium anticancer drug 5-fluorouracil (5-Fu) and sulphorhodamine B (SRB) were purchased from 
Sigma-Aldrich, St Louis, MO, USA. Fetal carbonate (NaCO3), HCl, MTT reagent, 
dimethylsulfoxide (DMSO), phosphate buffered saline (PBS) tablets, acetic acid and Tris EDTA 
were purchased from Merck, Darmstadt, Germany. Aluminium nitrate, Al(NO3)3. 9H2O, was 
obtained from C.C. Imelmann, Southdale, South Africa. The bovine serum (FBS) was purchased 
from Hyclone, GE Healthcare, Utah, USA. Eagles Minimum Essential Medium (EMEM), 
Penicillin/ Streptomycin, trypsin-versene were all obtained from Lonza Biowhittaker, 
Walkersville, USA. Human embryonic kidney (HEK 293) cells were provided by the Anti-viral 
gene therapy unit, Medical School, University of the Witwatersrand, South Africa. Human 
hepatocellular carcinoma (HepG2), breast adenocarcinoma (MCF-7) and colorectal cancer (CaCo-
2) cells were purchased from Highveld Biological (PTY) LTD., Lyndhurst, South Africa. All 
sterile tissue culture plastic ware was obtained from Corning, NY, USA. All reagents were of 





















All the ZnAl-LDH samples were synthesized using the co-precipitation. Briefly, 25.6 g of 
Zn(NO3)2 .6H2O (0.1M) and 18.75 g of Al(NO3)3.9H2 O (0.05M) for (ZnAl 2:1-LDH) and     25.6 
g of Zn(NO3 )2.6H2O (0.1M) and 12.8 g of Al(NO3)3.9H2 O (0.05M) for (ZnAl 3:1-LDH) were 
added into 150 ml of distilled 18 MΩwater, and mixed. Thereafter 53g of Na2CO3 was put in a 
beaker containing 600mL of water. This was stirred and the pH was adjusted to 11 using 0.1M 
NaOH. Al (NO3)3.9H2O and Zn(NO3)2.6H2O were subsequently added into the solution. The 
mixture was then aged overnight at 80 °C, after which the LDHs were washed with 18 MΩ water 
repeatedly until pH was neutralised. The slurries were first vacuum dried and then dried further 




4.3.3 ZnAl-LDH: 5-Fu synthesis 
 
 
The intercalation of 5-Fu into both the ZnAl-LDHs (2:1 and 3:1 respectively) was achieved using 
the reconstruction route. The procedure first involved the calcination of the respective LDHs in a 
horizontal furnace (Labofern PUB002) set at 400 °C for 8 hours under N2   atmosphere. Briefly, 
11.1 mg of the calcined ZnAl LDH powders, suspended in 20 mLof 5-Fu (0.0114 M in 18 M 
water, pH 8.0) solution, were vigorously stirred under N2 atmosphere for 24 hours to obtain the 




4.3.4 UV-Vis Spectroscopy. 
 
 
The encapsulation efficiencies (%EE) of the respective ZnAl nanoparticles was determinmed by 
centrifugation and UV-Vis spectroscopy. The respective ZnAl-5-Fu suspensions were centrifuged at 
12000 rpm for 5 minutes, and supernatants containing any free 5-Fu were assayed by UV-Vis 
spectroscopy (Biomate, Thermoscientific). The pellets were resuspended in 18 MΩ water and readings 
taken to measure absorbance of LDH bound 5-Fu. Absorbance readings were obtained at 266 nm and 









4.3.5 Powder X-Ray diffraction 
 
 
Powder X-Ray diffraction (XRD) was performed for the uncalcined (pure), calcined and drug 
conjugated ZnAl, using a Bruker D8 Advanced XRD analyzer (CuKa radiation) equipped with 
Bruker analysis software. In each of the runs, 0.5 g of the sample was used and signals were 




4.3.6 Fourier Transform Infrared Spectroscopy (FTIR) 
 
 
Infra-red (IR) spectra of the LDH and nanohybrids were obtained using a Perkin Elmer FTIR 
Spectrometer equipped with a Universal ATR sampling accessory using a diamond crystal. For 




4.3.7 Inductively Coupled Plasma Analysis-Optical Emission Spectroscopy (ICP-OES) 
 
 
Elemental detection and quantification of the metal content of the LDH and its complexes were 
obtained by inductively coupled plasma-optical emission spectroscopy (ICP-OES), performed on 
a Perkin Elmer Optima 5300 DV Optical Emission Spectrometer. Standard calibration curves were 





4.3.8 Electron Microscopy 
 
 
The ultrastructural morphology of the calcined ZnAl LDHs and their nanohybrids were examined 
under scanning electron microscopy (SEM) and transmission electron microscopy (TEM). For SEM, 
0.1 mg samples were examined using a ZEISS LEO 1450 scanning electron microscope, while for 
TEM, 1µl of each sample, was viewed in a Joel 1010 electron microscope (Tokyo, Japan) fitted 








4.3.9 Nanoparticle Tracking Analysis (NTA) 
 
 
NTA studies were performed using nanoparticle tracking analysis (NTA) using a Nanosight 
NS500 (Malvern Instruments, Worcestershire, UK). NTA analyses the sample by tracking the 
rate of the Brownian motion to the particle's size and zeta potential. The pristine nanoparticle as 
well as their respective nanohybrids were diluted to approximately 0.1 mg/mL in 18 MΩ water 




4.3.10 Drug release Studies 
 
 
Approximately, 1 mL of the ZnAl-5-Fu solutions (2:1 and 3:1 respectively) were dialyzed 
(MWCO of 7000 KDa), against 20 ml of PBS at pH 4 and pH 7, with stirring for 7 hours, as 
described previously (Maghsoudi et al., 2008). Samples (1 mL) were removed every hour for 




4.3.11. In vitro Cell Culture studies 
 
 
All cell culture studies were conducted under sterile conditions. Cells were routinely maintained 
in complete medium (EMEM containing 10% FBS, penicillin 100 µg/mL and streptomycin 100 
µ/mL), and visualized under an inverted microscope (Nikon TMS F 6V, Tokyo, Japan). Upon 
confluency, cells were trypsinized and split as desired into sterile cell culture flasks or counted 







4.3.12 MTT Cytotoxicity Assay 
 
 
The MTT assay or 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide assay is based 
on the principle that the MTT reagent (yellow) is converted into (purple) formazan crystals in 





the determination of the in vitro cytotoxic effects of anticancer drugs on multiple cell lines or 
primary patient cells (van Meerloo et al., 2011). 
 
Cytotoxicity was evaluated in four human cell lines: CaCo-2, HepG2, MCF-7 and HEK293. Cells were 
seeded at a density of 1 × 10
4
 cells/well in 100 μL in 24 well plates and incubated overnight at37°C. 
Thereafter, cells were treated with free 5-Fu and ZnAl-LDH-5-Fu (concentrations 12, 5µg/ mL, 25µg/ 
mL, 50µg/ mL and 100µg/ mL), and incubated for 48 hours at 37 °C. Assay was done in triplicate 
(n=3). Positive control cells containing no LDH or drugs were included. Medium was then removed 
and 100 µL of MTT reagent and 100 µL of medium was added and cells incubated at 37°C for 4 hours. 
The MTT/medium mixture was removed and 100 µL of DMSO was added to dissolve the formazan 
crystals formed. Absorbance readings were taken using a MR-96A microplate reader (Vacutec, 
Hamburg, Germany) at wavelength 570 nm, with 650 nm for background reading. The cell viability 
was calculated using the following formula: 
 
 




4.2.13 Sulphorhodamine B (SRB)  assay 
 
 
SRB is a protein dye that binds electrostatically and pH dependently to basic amino acids 
of cells. Mild acidic and mild basic conditions it can be extracted from cells and 
solubilized respectively, and hence determined spectrophotometrically (Vichai and 
Kirtikara, 2006). Cells were plated and treated with the free drug and LDH-Fu as for 
4.2.12. After 48 hours, cells were fixed by overlaying the growth medium with ¼ volume 
of cold 50% TCA, and incubated for 1 hour at 4 
º
 C. Cells were then rinsed with deionized 
water, air dried, and covered with 50 µL of 0.4% SRB solution for 20 minutes. Thereafter 
cells were washed with 1% acetic acid, and air dried, followed by the addition of 100 µL 
of 10 mM Tris-EDTA solution to solubilize the dye. The plate was then shaken (Stuart 
Scientific, platform shaker STR 6) for 5 minutes, and absorbance read at 565 nm, with 











4.3.14 Apoptosis Study 
 
The dual-staining method for apoptosis using acridine orange and ethidium bromide (AO/EB) was 
employed. Mechanism of cell death from exposure to free 5-Fu and LDH-5-Fu was determined 
using 100 mg/mL of both dyes (1:1 ratio in PBS). Cells were plated in a 24 well plate at a seeding 
density of 1.2x10
5
 cells/well, and incubated as in 4.3.12. Free and LDH bound 5-Fu (20 µL each) 
were then added to cells and cells incubated for 48 hours at 37 °C. Thereafter, cells were washed 
(PBS, 100 µL) and then covered with 15 µL of the dual stain for 5 minutes. Cells were visualized 
using an Olympus inverted fluorescent microscope with a CC12 fluorescent camera (Olympus 
Co., Tokyo, Japan) at X200 magnification, and apoptotic indexes (AI) were calculated using the 
following formula; 
 
Apoptotic Index = Number of apoptotic cells 





4.3.15 Statistical Analyses 
 
 
All statistical analyses were performed using Graph pad prism 5.0 (GraphPad Software, Inc., San 
Diego, CA), one-way analysis of variance (ANOVA). Differences between groups were 





4.4 Results and Discussion 
 
 
4.4.1 Synthesis of ZnAl-LDH 
 
 
ZnAl 2:1-LDH and ZnAl 3:1-LDH were successfully synthesized. Both LDHs had the characteristic 
pristine white appearance, but upon calcination changed to a light grey color (Figure 4.1). This was 
probably due to the decomposition and decarboxylation of the LDHs (Starukh et al., 2016). 
Decomposition of the LDHs essentially leads to loss of its structural integrity, which is then 
converted to a mixture of oxides (zinc and aluminum). Thus the particle loses some of its original 

































Figure 4.1: Synthesized LDHs (a) ZnAl 2:1 pristine (b) ZnAl 3:1 pristine (c) ZnAl 3:1-5-Fu calcined (d) 





4.4.2 UV-Vis spectroscopy 
 
 
As 5-Fu is intercalated within the ZnAl LDHs, it is held together by electrostatic forces within the 
cationic layer of the LDHs. Thus to ascertain this, UV-Vis spectroscopy was conducted. UV-Vis 
spectroscopy confirmed the actual binding of 5-Fu within the LDH (Figure 4.2). This was observed 
as a shift in the wavelength from 266 nm (5-Fu) to 265 nm respectively for the nanohybrids.  Drug 
encapsulation efficiencies were then calculated for both nanohybrids to quantitate the amount of 
bound drug (Table 4.1). These results displayed a much higher binding efficiency for ZnAl 3:1-5-
Fu than ZnAl 2:1, which indicates a slightly higher electrostatic interaction of the drug with the 
second nanohybrid. This could be an advantage for the drug, as it will be protected from harsh 
physiological reactions, but may also be a disadvantage in a sense that the drug might be 














    
 









Table 4.1 Al-LDHs Encapsulation Efficiencies (% EE) 
 
Nanoparticle name Nanohybrid formula Encapsulation efficiency 
  (%EE) 
   
ZnAl 2:1 ZnAl 2:1-5-Fu 64.92 
   
ZnAl 3:1 ZnAl 3:1-5-Fu 56.56 




4.4.3 XRD Analysis. 
 
XRD analyses (Appendix B.1), revealed the typical well crystalized hydrotalcite structure for 
ZnAl LDHs (2:1 and 3:1), both exhibiting fairly sharp and symmetric 00l reflections, (003) (006) 
and (009) which are characteristic of a lamellar material. Calcined ZnAl 2:1 And 3:1 LDH 
displayed loss of structural integrity as seen with the indistinguishable peak patterns around 2 theta 
19 º and 18 º respectively. All ZnAl-LDHs and nanohybrids displayed a (110) reflection, however 
there was a slight shift in the peaks in then nanohybrids due to the intercalation of 5-Fu within the 
gallery space of the respective LDHs (Jin et al., 2010).                                           
































4.4.4 Fourier Transform Infrared Spectroscopy 
 
For all the LDHs, the bands near 3000 cm-1 corresponded to the vibration bands of hydroxyls (O-
H). A shift of the O-H vibrational band to a higher wavelength with the increase in Zn/Al ratio 
was observed. Such a change is due to the smaller ionic radius of Al
3+
 in comparison to the larger 
radius of Zn2+ (Tong et al., 2011). Thus this leads to a higher electrostatic interaction between Al3+ 
and OH versus the Zn+2 and OH interaction with the increased Zn/Al ratio. IR-spectra of 5-Fu 
exhibited characteristic peaks around 1600 cm-1 attributed to vibration stretching of C=O in 
amide, and C-N stretching. These characteristic peaks were also observed on the two respective 
nanohybrids, ZnAl 2:1-5-Fu and ZnAl 3:1-5-Fu. Hybridization, peaks corresponding to C=O in 
imide disappeared, and a broad band corresponding to C=C, C=N, and C=O stretching vibration 
appeared, which was in good agreement with the previous report on 5-Fu-incorporated LDH. 
Interestingly the peaks at 1636.18 cm
−1
 (ZnAl 2:1-5-Fu) and 1636.79 cm
−1
 (ZnAl 3:1-5-Fu) 
confirmed interaction of 5-Fu with a cationic substance, further verifying intercalation of 5-Fu 




4.4.5 Inductively coupled plasma-optical emission spectroscopy (ICP-OES) 
 
Inductively coupled plasma-optical emission spectroscopy (ICP-OES) was performed on the 
ZnAl-LDHs (2:1 and 3:1) and their nanohybrids confirmed the presence of magnesium and 




4.4.6 Electron Microscopy (SEM and TEM) 
 
 
Under SEM, both ZnAl 2:1-LDH and ZnAl 3:1, displayed the characteristic hexagonal shape, a 
distinguishing feature of these nanoparticles (Figures 4.3-4.4). Their sizes as assessed under EM 
ranged from 35 nm for the LDHs to 60 nm for the nanohybrids. Since this provides a limited 
view, a more accurate size distribution was obtained from NTA studies (4.3.7). Agglomeration 
of the nanoparticles was observed and indicated quite a unique dispersity property of the LDHs 
(both ZnAl 2:1-LDH and ZnAl 3:1). Lateral sizing and thickness of the nanoparticles was 






characteristic LDH structure, possibly due to the calcination process essentially decomposing the 
distinct house of cards structure and the subsequent loss of interlayer species (thus the loss in 
thickness) (Figures 4.3b-4.5b) (Patzkó et al., 2005). Their structure was reformed after 5-Fu 
intercalation. This phenomenon of reconstruction after calcination of the LDHs allows for the 
intercalation of the drug safely into the interlayer space whilst also reconstructing the vertices of 
the respective LDHs. TEM further confirmed the formation of true LDHs (both ZnAl 2:1-LDH 
and ZnAl 3:1). The lateral sizes all LDHs were in the same range as that observed with SEM and 
the dispersity of the LDH discs was also visualized. The aggregation of these nanoparticles seemed 
a common feature. TEM of the calcined LDHs further confirmed a loss in the original hexagonal 
shape of the LDHs (Figures 4.4.-4.5), due to their exposure to high temperatures (400 
º
C) for a 













          
Figure 4.4 SEM micrographs of (a) ZnAl 3:1, (b) Calcined ZnAl 3:1 and (c) ZnAl 3:1-5-Fu (Bar 
</=150nm).  
 
(a)                               (b)                                         (c) 
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   4.4.7 Nanoparticle tracking analysis (NTA) 
 
Previous research has highlighted the importance of positively charged nanomaterials with regards to 
their favorable interaction with cellular membranes, stating that a net positive charge leads to their 
enhanced cellular uptake of, and subsequently the uptake of intercalated species (Kim et al., 2014). 
However, net surface charge of ZnAl-LDHs, like most other LDHs, is largely affected by the surface 
coating of the molecules, the concentration of electrolytes, and the type or concentration of solutes in 
the suspending medium (Kim et al., 2014). NTA served to establish the zeta potentials in addition to 
the sizes of the ZnAl-LDHs and their respective nanohybrids (Table 4.1, Appendix B.3). The net zeta 
potentials observed for ZnAl 2:1 was ~ above 50 mV and for ZnAl 2:1-5-Fu it was ~ 37.3 mV The 
same trend was observed for ZnAl 3:1 (52.34 mV) and its nanohybrids ZnAl 3:1-5-Fu (23.24 mV). 
These readings confirm the colloidal stability of these LDHs and the reduced risk of systemic 
(a)                               (b)                                         (c) 
)  
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aggregation. Another important factor to consider is that the anionic 5-Fu plays a part in the 
inhibition of the hydroxide layer growth, thus resulting in a slight decrease in the net zeta charge. 
It has also been reported that the intercalation of 5-Fu plays an important role in the hydrodynamic 
size distribution of the nanohybrids (Chen et al., 2014b). The two LDHs had average sizes of 100 
nm (ZnAl 2:1) and 150 nm (ZnAl 3:1) with correspond nanohybrids appearing slightly smaller 
(99 and 110 nm respectively). These reports do not necessarily reflect the percentage uptake of the 





Table 4.1: Net Zeta potentilas of ZnAl 2:1. ZnA 2:1-5-Fu, ZnAl 3:1 and ZnAl 3:1-5-Fu 
 
PROPERTY    LDH SAMPLE   
 
Sample name  ZnAl 2:1  ZnAl 2:1-5-Fu  ZnAl 3:1  ZnAl 3:1-5-Fu 
 
         
 





















4.3.8 Drug release studies 
 
The drug release profile of the ZnAl-LDH with corresponding nanohybrids was studied for both 
nanohybrids (2:1and 3:1) (Figure 4.7). At pH~4 it was observed that both nanohybrids had a burst 
of drug release by t=1. This is due to the LDH being exposed to a low pH leading to its rapid 
disintegration and subsequent drug release. This property leads to a controlled release of 5-Fu once 
the cationic layers separate. At t=1, 25 % of 5-Fu had been release for the first nanohybrid and 29 
% had been released for the second nanohybrid. Cancerous cells generally have a lower pH due to 
their high often intracellular anaerobic processes (Gerweck and Seetharaman, 1996). This could 
prove to be the advantage for the LDHs, as they will only fully disintegrate at a low pH, whilst 








This trend continued on until t=7, where for ZnAl 2:1-5-Fu 70% of the drug was released and for 
ZnAl 3:1-5-Fu, 60 % of the drug had been released.  
Hence this slow release allows for a prolonged effect of the drug until 100 % of the drug is released, 
which is expected to occur after 7 hour, and needs to be further investigated. It has been previously 
reported that LDHs offer a system of controlled release for drugs (Kim et al., 2014). 





4.4.9 MTT Cytotoxicity Assay 
 
To determine the cytotoxicity effects of the free 5-Fu and 5-Fu loaded LDHs in the four human cell 
lines (HEK293, MCF-7, Hep-G-2 and CaCo-2), the MTT cell viability assay was carried out. From 
the results it can be noted that the LDH encapsulated 5-Fu offered a gradual drug release which led 
to a steady decline in cell survival as the concentration of the drug increased, whilst at the same 
concentration significant cell death was observed for cells assaulted with free 5-Fu (Figures 4.8- 








    
This rapid cell death for cells treated with pure 5-Fu indicates a less controllable and less predictable 
mode of delivery for the drug, providing immediate but probably not a sustained effect. Hence, the 
5-Fu loaded LDHs provide a more prolonged effect of the drug. The significant difference in cell 
survival between ZnAl-5-Fu treated cells and those treated with free 5-Fu was further evident with 
the IC50 values (Table 4.2). 
ZnAl-5-Fu treated cells had a significantly higher IC50 values, ranging between 49.55 -77.05 
g/mL, while lower IC50 values ranging from 22.12 -54 g/mL were observed for the cells treated 







Figure 4.8 : MTT assay of ZnAl-3:1-5-Fu and free 5-Fu at concentrations12.5 µg/mL, 25 µg/mL, 50 
µg/mL and 100 µg/mL) in HEK293, MCF-7, HepG2 and CaCo-2 cell lines [data presented as means SD 
(n=3) (*p < 0.05)]. 
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Figure 4.9: MTT assay of ZnAl-3:1-5-Fu and free 5-Fu at concentrations12.5 µg/mL, 25 µg/mL, 50 µg/mL 
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Table 4.2: IC50 (µg/mL) values for ZnAl 2:1-5-Fu, ZnAl 3:1-5-Fu and free 5-Fu. 
 
Cell line ZnAl 2:1-5-Fu Free 5-Fu ZnAl 3:1-5-Fu Free 5-Fu 
     
  IC50 values in µg/mL  
HEK293 65.50 41.94 69.39 22.95 
     
MCF-7 72.83 33.25 70.33 25.25 
     
HepG2 68.55 31.69 77.05 64.84 
     
CaCo-2 59.55 31.07 49.55 21.07 







4.4.10 Sulphorhodamine B (SRB) assay 
 
 
The SRB assay has been routinely used to evaluate drug-induced cytotoxicity especially in anticancer 
drug screening (Voigt, 2005). The principle behind this assay is based on the pH dependent electrostatic 
binding of the SRB protein dye to basic amino acid residues of cells. The SRB assay conducted across 
four the cell lines (HEK293, MCF-7, HepG2 and CaCo-2 cell lines), further confirmed that 
treatment with the LDH encapsulated 5-Fu offered a steady release of the drug to the cells, in 
comparison to the cells treated with free 5-Fu (Figures 4.10-4.11). Due to the LDHs being 
disintegrated at lowered pH this allows for the release of the LDH contents to the cancerous cell 
lines in a selective fashion as these cells have a lowered pH. Interestingly, in this assay both 
nanohybrids were least tolerated in the MCF-7 and CaCo-2 cell lines with cell death as much at 90 
% at the highest concentration. Hence, some degree of cell specificity was observed, but this cannot 
be considered significant without further optimization studies. The cytotoxicity profiles were 
further confirmed by the IC50 values calculated (Table 4.3). Although cell specificity was not clear, 
the dose dependent activity of both LDHs were evident. The SRB assay further corroborated the 








Figure 4.10: SRB assay of ZnAl-2:1-5-Fu and free 5-Fu at concentrations 12.5 µg/mL, 25 µg/mL, 50 
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Figure 4.11: SRB assay of ZnAl-3:1-5-Fu and free 5-Fu at concentrations12.5 µg/mL, 25 µg/mL, 50 




Table 4.3: IC50 (µg/mL) values for ZnAl 2:1-5-Fu, ZnAl 3:1-5-Fu and free 5-Fu. 
 
Cell line ZnAl 2:1-5-Fu Free 5-Fu ZnAl 3:1-5-Fu Free 5-Fu 
     
  IC50 values in µg/mL  
     
HEK293 76.35 41.94 69.75 22.25 
     
MCF-7 51.38 30.25 43 27.5 
     
HepG2 72.42 35.69 60.05 22.12 
     
CaCo-2 55.05 41.07 32.84 24.8 




4.4.11 Apoptosis studies  
 
Free 5-Fu and ZnAl-LDH encapsulated 5-Fu were further investigated after cytotoxicity 
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acridine orange and ethidium bromide (AO/EB) can be used to visualize and identify apoptotic-
associated changes in cells (Liu et al., 2015). Some of these morphological changes that can be 
easily identified are (i) rounding off cells (ii) shrinkage (iii) condensing of chromatin and, (iv) 
fragmentation of the nucleus. Acridine orange is a vital dye that stains both live and dead cells (Liu 
et al., 2015). Ethidium bromide stains cells that have lost membrane integrity only. Live cells will 
appear uniformly green. Early apoptotic cells stain green and have green dots in the nuclei due to 
chromatin condensation and nuclear fragmentation. Late apoptotic cells incorporate ethidium 
bromide and therefore stain orange, however in contrast to necrotic cells, the late apoptotic cells 
will show condensed and often fragmented nuclei. Necrotic cells stain orange, but have a nuclear 
morphology resembling that of viable cells, with no condensed chromatin (Kasibhatla et al., 2006). 
The apoptosis induction was visualised under a fluoroescent microscope. Cells treated with free 5-
Fu displayed an increased apoptotic pattern when compared to cells treated with ZnAl-5-Fu (2:1 
and 3:1). The results also almost no apoptotic induction in cells treated only with ZnAl LDH. This 
confirmed that the LDH’s toxicity is almost negligible. The overall trend shows that free 5-Fu 
significantly increases apoptosis in all cell lines while LDH bound 5-Fu show lower apoptotic 
events (Figures 4.12 -4.13). Apoptosis indexes calculated also confirm this trend (Table 4.4). Using 
the dual staining method, live cells (L) usually appear green, early apoptotic cells appear yellow 



























    









































Figure 4.12: Fluorescent images of apoptosis induced by ZnAl 2:1-5-Fu and Free 5-Fu on HEK293, 
MCF-7, HepG2 and CaCo-2 cell lines (L=Live cells, A=Apoptotic cells, LA= Late Apoptotic cells 
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Figure 4.13: Fluorescent images of apoptosis induced by ZnAl 3:1-5-Fu and free 5-Fu on HEK293, 
MCF-7, HepG2 and CaCo-2 cell lines (L=Live cells, A=Apoptotic cells, LA= Late Apoptotic cells 
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Table 4.4: Apoptotic Index (AI) of cells exposed to ZnAL-2:1-5-Fu, ZnAl 3:1-5-Fu and free 5-Fu 
 
  APOPTOTIC INDEX (AI)   
       
Cell lines Control Cell Control ZnAl 2:1-5- Free 5-Fu ZnAl 3:1- Free 5-Fu 
  LDH Fu  5-Fu  
HEK293 0.00 0.00 0.2 0.2 0.1 0.25 
       
MCF-7 0.00 0.00 0.121 0.21 0.12 0.21 
       
HepG2 0.00 0.00 0.21 0.35 0.2 1.06 
       
CaCo-2 0.00 0.00 1.2 0.2 0.3 1.01 










The ZnAl-LDH system evaluated, has shown potential to be utilized as a drug delivery system. This 
system is of suitable size, with high zeta potentials that favour colloidal stability and cellular uptake. 
Furthermore, this system offers a dose dependent cytotoxicity, coupled with a controlled system of 
drug release over a period of time. The disintegration of these LDHs at low pH, furthermore, allows 
for the selective release of its contents into cells with a lowered pH such as the cancerous cells, 
thereby offering selective protection and limited collateral damage to normal cells. Overall, these 
ZnAl LDH based drug delivery systems, are easy to synthesize, are cost effective, have favourable 
size distributions, are relatively stable, and importantly display controlled drug release. All these 
properties bode well for future use of these LDHs in nanomedicine. 
Future studies and recommendations include the optimization of the systems with polymers such 
as polyethyleneglycol for steric stabilization, addition of a targeting ligand for cell/cancer specific 
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Overall results from chapters 3 and 4, confirm that these LDHs are capable of being drug delivery 
vehicles for anionic drugs.  The two MgAl-LDHs synthesized differed in many aspects, not only 
is their ability to deliver 5-Fu, but in their unique release of the nanoparticle’s contents. We found 
that although these drug delivery systems are very well capable of delivering 5-Fu in particular, a 
few improvements can be made to increase these nanoparticles’ encapsulation efficiencies to well 
over 70% encapsulation. LDH encapsulated 5-Fu may be effective against the certain forms of 
cancer as its mechanism of action was gradual and more controlled. The two MgAl-LDHs (2:1 
and 3:1) were found to embody a very crucial aspect that is much needed in drug delivery, i.e. the 
ability to selectively release contents in a lowered pH, which favours cancer cells, and in turn 
offering partial protection to normal cells (pH 7.4) Experimental analyses revealed that true MgAl-
LDH nanoparticles were synthesized and that reconstruction allowed for the successful 
incorporation of the anticancer drug 5-Fu to form the nanohybrids MgAl 2:1-5-Fu and MgAl 3:1-
5-Fu. Finally, free 5-Fu caused greater cell death than LDH bound 5-Fu, enforcing the LDH slow 
release properties. The ZnAl-LDHs (2:1 and 3:1) have also been found to be an effective drug 
delivery system for the delivery of 5-Fu. This nanoparticle allowed for a much more stable 
nanohybrid system inside which the anticancer drug can be encapsulated and delivered to be 
affected cells. Furthermore, it allowed for the steady release of 5-Fu to the cells under 
investigation. This property of ZnAl LDH, is similar to previously reported LDH delivery systems 
and hence require future focused studies. High IC50 values observed for the nanohybrid against the 
cells treated with pure 5-Fu, further revealed that the gradual release offered by this nanoparticle 
allows for the calming of 5-Fu’s aggressive chemotherapeutic effects. 
 
The simplistic and cost effective development of the LDHs (both MgAl and ZnAl) nanoparticles 
presents an opportunity for the development of DDSs that are inexpensive as well as quick to 
manufacture. These nanoparticles can also help to alleviate the cost of chemotherapy to millions 
of people affected by cancer. The unique properties of these nanoparticles mean a more targeted, 





discovery of new anticancer drugs, but rather the development of more effective and less costly 





5.2 Future improvements and prospects. 
 
 
1. A more targeted mode of delivery with LDHs can be achieved by the incorporation of 
coating targeting moieties onto the surface of this nanoparticle. 
 
2. The incorporation of other drugs in these LDHs is also an important aspect to look at, 
either as individual drug formulations or combination-type of drug delivery. 
 
3. The unique chemistry of the intercalation of substances in LDHs is another aspect worth 
looking at, in terms of bond chemistry and electrostatic interaction of incorporated 
substances 
 
4. Further studies using more cell lines in vitro for a broader spectrum of cytotoxicity 
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Figure 3 :FTIR Spectrum of 5-Fu 
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Figure 5 :FTIR spectratrum of MgAl 2:1-5-Fu 
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FTIR Bond absorption frequencies recorded for MgAl 2:1, MgAl 2:1-5-Fu, MgAl 3:1MgAl 3:1-























Figure 7 :FTIR spectrum of MgAl 3:1-5-Fu 
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Figure 15: FTIR spectrum of 5-Fu. 
Figure 16 : FTIR spectrum of ZnAl 2:1. 
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Figure 17:FTIR spectrtrum of ZnAl 2:1-5-Fu. 
Figure 18 :FTIR spectrum of ZnAl 3:1. 
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Figure 19 :FTIR spectrum of ZnAl 3:1-5-Fu. 
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APPENDIX C  
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